empanelment of drug testing laboratories - Kerala Medical Services ...

KERALA MEDICAL SERVICES CORPORATION LIMITED 

(A Government of Kerala Undertaking) 

Thycaud P.O, Thiruvananthapuram, KERALA 695 014 

INVITATION OF EXPRESSION OF INTEREST 

for 

EMPANELMENT OF DRUG TESTING 

LABORATORIES 

(EOI No: KMSCL/QC/EOI/FY13-15/02 

Name of EOI Responder: 

Address: 

Signature of EOI Responder: 

Last date and time for the receipt of EOI Response: 11 am; 02/01/2013 

NOT TRANSFERABLE 

For details; 

www.kmscl.kerala.gov.in 

Email: kmscltvm@gmail.com

Sl. 

No. 

Table of Contents 

DESCRIPTION 

1 SECTION – I INTRODUCTION 2 

2 SECTION – II INVITATION OF EOI 4 

3 SECTION – III EOI SCHEDULE 7 

4 SECTION – IV SPECIFIC CONDITIONS OF EOI 8 

5 SECTION – V 

6 ANNEXURES 

GENERAL CONDITIONS OF 

CONTRACT 

PAGE 

NO. 

7 Annexure – I Checklist 33 

8 Annexure – II Application Form 35 

9 Annexure – II (a) Details of Personnel in QC Department 37 

10 Annexure – II (b) 

List Of Sophisticated Analytical Drugs 

Equipments /Apparatus Available 

In The Laboratory 

11 Annexure – II (c) Facilities in the Microbiological Section 39 

12 Annexure – III 

13 Annexure –IV 

Format of Bank guarantee of Earnest 

Money Deposit 

Form Proforma for Performance 

Statement 

14 Annexure – V Annual Turnover 43 

15 Annexure –VI Declaration 44 

16 Annexure –VII Details of Laboratory 45 

17 Annexure – VIII Consent Letter of the Offerer 46 

18 

Annexure -IX 

Format of Bank guarantee for Security 

Deposit 

19 Annexure – X Agreement 49 

20 Appendix List of Drugs 55 

KMSCL: EOI for Empanelment of Drug testing Laboratories Page 1 

10 

38 

40 

42 

47

SECTION I 

INTRODUCTION 

1.1. The Kerala Medical Services Corporation Limited - KMSCL is a fully owned 

Government of Kerala company set up in 2007 for providing services to the 

various health care institutions under the Department of Family Welfare and 

Health. One of the key objectives of the KMSCL is to act as the central 

procurement agency for all essential drugs and equipments for all health care 

institutions under the department. 

1.2. Kerala, one of the progressive States in India, has been in the forefront of 

public health initiatives. The health care indices are comparable to those of 

the developed nations. With the creation of large numbers of trained doctors 

and nurses, extensive networks of hospitals, and a primary health centre 

(PHC) in every village, Kerala had achieved the status of a health model. It 

has better access to health services than most populations of the lessdeveloped 

world. In short, the hall mark of Kerala model is low cost of health 

care, universal accessibility and availability even to the poor sections of the 

society. 

1.3. With the setting up of the Kerala Medical Services Corporation Ltd, the 

shortage of essential drugs in the hospital has become a matter of past. The 

KMSCL procures around 952 essential drugs and other medical supplies. The 

drugs are stored in about 20 warehouses in all the districts and distributed to 

nearly 1500 government institutions. The drug samples are drawn from the 

warehouses and sent to empanelled labs without identity details, for QC 

testing. The Corporation has at present 8 NABL accredited empanelled 

laboratories. The objective of this EOI process is to increase the number of 

labs to be empanelled to a minimum of 25 this time. 

1.4. The Corporation is in the pursuit of improving the quality standards of the 

drugs administered in the hospitals. A series of measures for this purpose was 

introduced recently. Now the standing instruction is that as and when a new 

batch arrives, all warehouses are to draw the samples and sent by courier to 

the QC section of the Head Office within 24 hours. The QC, in turn, have to 

despatch the samples of every batch arriving from different warehouses to 

empanelled labs within 48 hours. There is also coding to ensure that the 

identity of the batch and the manufacturer are kept secret, till the results are 

obtained and published. Multiple samples from the same batch are randomly 

sent to more than one empanelled lab to test the efficacy of the labs and 

KMSCL: EOI for Empanelment of Drug testing Laboratories Page 2

consistency of the products. The Corporation has published a QC manual of 

its own, an initiative of first of its kind in the country, to clearly lay down in 

unambiguous terms the quality tests to be performed. The manual has 

prescribed some additional tests other than what has been prescribed by the 

pharmacopeia. The common tendering system for all the essential drugs, 

sutures, cold chain products, medical devises, X-Ray items etc were split up 

into 8 tenders and higher prequalification criteria has been prescribed in order 

to ensure that only quality drugs and supplies are procured and distributed. 

This EOI process is undertaken to select the QC labs called as empanelled 

labs, so as to ensure that the quality requirements specified by the 

Corporation are met. 

1.5. Every paise spent by the Corporation is public money and hence accountable. 

It is also essential while dealing with public money that utmost transparency 

has to be maintained in the procurements of the Corporation. All decisions 

will be published from time to time on our website www.kmscl.kerala.gov.in. 

1.6. Offerers could prefer appeal to the government against all decisions of the 

Corporation. 

Date:13/12/2012 

Looking forward for a long standing relation with you. 

Best wishes, 

Sd/- 

Managing Director, KMSCL 

& 

(EOI Inviting Authority) 


SECTION – II 

INVITATION OF EXPRESSION OF INTEREST 

2.1. The Kerala Medical Services Corporation Limited (herein after referred as 

‘KMSCL’) invites applications for Empanelment of Drug Testing Laboratories 

for the Analysis of Drugs, Medical Devices, Supplies, Surgical Sutures etc more 

specifically mentioned in Appendix procured by the KMSCL for a period of 

two years from the Date of Acceptance. 

2.2. The drug testing laboratories which are currently empanelled by the 

corporation need not participate for those qualified products, but can 

participate for other products. 

2.3. All the drug testing laboratories across the country other than those rejected 

due to non compliance of pre-qualification criteria in the EOI (EOI No: 

KMSCL/QC/EOI/FY 11-13/01) invited by the corporation are eligible provided 

they have the eligibility criteria as prescribed under the pre-qualification 

criteria (clause-4.2.) 

2.4. The expression of interest process is divided into two: 

2.4.1 Scrutiny of technical documents submitted before the scheduled 

date and time. 

2.4.2 Inspection of the short-listed labs by a technical committee on 

behalf of the Corporation and selection of the lab. 

2.5. Those analytical labs which are willing to undertake the testing of the drugs 

and other medical supplies at the rates prescribed in the Appendix and are 

willing to accept the terms and conditions as prescribed under the EOI 

document are eligible to be selected as the “empanelled lab of the KMSCL”. 

2.6. The rates of the testing of drugs and supplies are pre-fixed, taking into account 

the costs of reagents, capital investments in equipments/infrastructure and the 

labour cost for the analysis. The offerers shall be willing to undertake the test 

subscribing to terms and conditions of this EOI document at these pre-fixed 

rates. 

2.7. The delivery of results in time and the consistency of the analysis results are 

the most important factors to be adhered to by the selected Analytical Testing 

Laboratories hereinafter called empanelled labs. 


2.8. There shall be a pre-offer meeting at the head office at the date and time 

prescribed in section III to clear the queries of the prospective offerers. The 

prospective offerers may also request changes in terms and conditions, which 

shall be decided by the Corporation based on merit of the individual requests. 

It is not necessary that all the requests from the prospective offerers shall be 

complied with; rather this is to ensure the transparency of the EOI process and 

also to ensure that the market conditions are taken into account while 

prescribing the requirements of the Corporation. 

2.9. Those Labs which are found to comply with the requirements of the 

Corporation will be shortlisted, after publishing the objections / clarifications / 

inadequacies in submitting the information / documents and giving 

opportunity for representing their queries. Any decision taken by the 

Corporation shall be published on the website and complaints / objection shall 

be disposed of before proceeding to the next stage. 

2.10. The labs shortlisted after scrutiny of the documents submitted as part of the 

EOI shall be inspected by a team of officers of the government deputed by the 

Corporation after giving short notice. 

2.11. At any time before the submission of EOI, KMSCL may, for any reason, 

whether on its own initiative or in response to a valid clarification requested 

by a prospective offerer, carry out amendment(s) to this EOI document. The 

amendment will be made available in the website (www.kmscl.kerala.gov.in) 

and will be binding on all prospective offerers. KMSCL may at its discretion 

extend the deadline for the submission of proposals. 

2.12. The period of contract shall be two years. The EOI responders shall give price 

firmness for two years from the date of agreement. 

2.13. EOI responses that are incomplete in any respect or those that are not 

consistent with the requirements as specified in this document or those that 

do not adhere to formats, wherever specified may be considered nonresponsive 

and may be liable for rejection and no further correspondences 

will be entertained with such offerers. 

2.14. Canvassing in any form would disqualify the applicant. 

2.15. The envelope containing the EOI Response is to be super scribed with the title 

"Expression of Interest for Empanelment of Drug Testing Laboratories for the 

years 2013-15". 


2.16. The EOI Responder must submit the response in hard copy in sealed 

envelope either in person or through post so as to reach the Head office on or 

before the date and time specified in Section III and addressed to: 

The Managing Director 

Kerala Medical Services Corporation Limited, 

Thycaud P.O., 

Thiruvananthapuram, 

Kerala -695 014 

2.17. The date and time as well as other details are specified in Section III. 

2.18. For further clarifications contact: 

Phone No: 0471- 2337454 & 0471-4019926 

Email: kmsclqc@gmail.com 


3.1 Important details of the EOI: 

SECTION – III 

EOI SCHEDULE 

1. EOI No. KMSCL/QC/EOI/FY12-14/02 

2. Cost of EOI Document `1000/- 

3. Earnest Money Deposit `25,000/- (refundable) 

4 

Form of Earnest 

Money Deposit 

5. Validity of EMD 

6. Security Deposit `50,000/- 

7. 

8. 

Validity of Security 

deposit 

Form of security 

deposit 

9. Pre-Offer meeting fee `500/- 

3.2 Important dates: 

Sl. 

No. 

1 

2. 

3. 

4. 

5. 

Demand Draft/Bank Guarantee as per 

Annexure III 

180 days from the date of opening of 

technical document 

30 months from the date of execution of 

agreement 

Demand Draft/Bank Guarantee as per 

Annexure IX 

Particulars Date and time Venue 

Date and time of 

commencement of sale of EOI 

document 

Date and time of Pre- offer 

meeting 

Last date and time of sale of 

EOI document 

Last date and time of receipt of 

offers 

Date and time of opening of the 

offers 

6. Date of Inspection of the Lab 

13/12/2012 

(during office hours) 

11am; 19/12/2012 

5 pm; 01/01/2013 

11 am; 02/01/2013 

2.30 pm; 02/01/20132 

To be informed to the 

qualifying EOI 

responders 


Head Office, KMSCL.

4.1 Time Limits Prescribed: 

SECTION – IV 

SPECIFIC CONDITIONS OF EOI 

4.1.1 On empanelment and entrustment of the job, the Analytical Laboratory 

should furnish the test reports within15 days from the date of receipt of the 

samples of Tablets, Capsules, Pessaries, Ointments, Powder and Liquid 

Oral Preparations and within 30 days from the date of receipt of the 

sample of sterile preparations. 

Note: - The date and time of delivery of samples at the empanelled labs 

will be submitted by the couriers of the Corporation as proof of delivery 

(POD) and shall be obtainable by the lab from the Corporation. The time 

period shall be calculated from the date noted in the POD, which shall be 

binding on the empanelled lab. 

4.2 Prequalification Criteria: 

4.2.1 Only Analytical Laboratories having License under the Drugs and 

Cosmetics Act, 1940 and with NABL accreditation are eligible to apply. 

4.2.2 The offerers should be in the field of testing and analysis of drugs for the 

last three years. 

4.2.3 The labs shall have an average annual turnover of `25 lakhs for the last 

three consecutive years .i.e., for the period, 2009-10, 2010-11 and 2011- 

2012. 

4.2.4 Laboratories fully owned by the Government / PSUs, Reputed Research & 

Development Laboratories attached to Scientific/Research Institutions are 

exempted from the turnover criteria. 

4.2.5 Preference shall also be given to labs holding WHO, UNICEF or ISO 

Certification. 

4.2.6 An Analytical Laboratory, which is independent (and not part of a 

manufacturing activity) is only eligible to participate in the EOI process. 

4.2.7 The offerers could be any analytical lab located any where in India, which 

qualifies as per the pre-qualification criteria, but should be able to comply 

with the time frame prescribed under section 4.1. 


4.2.8 The offerers should have undertaken analysis of drugs and supplies of 

similar nature for at least three Government departments/ institutions / 

reputed manufacturers of drugs & supplies during the last three years. 

4.2.9 The offerer should not be a lab blacklisted by KMSCL or blacklisted/ 

debarred by any other State / Central Government’s organization. 

4.3 Methodology of testing and reporting conditions are clearly mentioned in 

the clause No.5.25 and all the testing procedures are laid down on QC 

manual of KMSCL modified from time to time which is published in the 

official website and but due to the volume, the offerers are expected to 

download and to ensure whether they have the technical capability to 

undertake analytical / testing facilities as per the procedure mentioned in it. 

Selection of samples sending to the empanelled labs will be by a computer 

programme. 

4.4 Penalties for deviation in the time limit prescribed in clause No.4.1 and 

furnishing of inconsistent reports are detailed in clause No.5.27. 

Note: - Furnishing of inconsistent test results three times or more in a year 

will lead to blacklisting of the empanelled labs. 


5.1 Contents of the EOI Document: 

SECTION-V 

GENERAL CONDITIONS OF CONTRACT 

This EOI Document contains the following: 

5.1.1 Introduction (Section I) 

5.1.2 Invitation of Expression of interest (Section-II) 

5.1.3 EOI Schedule (Section-III) 

5.1.4 Specific Condition of EOI (Section-IV) 

5.1.5 General conditions of Contract (Section-V) 

5.1.6 Annexures 

5.1.7 Appendix 

Note:- QC manual prepared by the Corporation modified from time to 

time have been hosted in the official website and this also forms 

the essential part of EOI document. 

5.2 Responsibility of verification of contents of EOI document 

5.2.1 Purchasers of the EOI form shall examine all instructions, forms, terms and 

specifications in the EOI Document and verify that all the contents 

mentioned under clause 5.1, are contained in the 'EOI Document'. 

5.2.2 Failure to furnish any information required by the EOI documents and 

submission of an offer not substantially responsive to it in every respect 

shall be at the offerer’s risk and may result in the rejection of the offer, 

without any further notice. 

5.3 EOI Document 

5.3.1 The terms and conditions governing the Empanelment of labs are 

contained in this "EOI Document". 

5.3.2 The document can be downloaded from website www.kmscl.kerala.gov.in. 

The offerers shall attach a separate Demand Draft / Bank Guarantee 

towards EMD, failing which the offer will be rejected. 

5.4 Guidelines for preparation of EOI 

5.4.1 The offerer shall bear all costs associated with the preparation 

and submission of its EOI and Kerala Medical Services Corporation Ltd., 


Thiruvananthapuram, will in no case be responsible or liable for these 

costs, regardless of the conduct or outcome of the EOI process. 

5.4.2 It is compulsory to provide a check list as per Annexure I as facing sheet for 

the EOI offers submitted so as to enable the Corporation to prima facie 

verify the compliance of submission of requisite documents at the time of 

opening of EOI. 

5.4.3 Language of EOI: - The EOI prepared by the offerer and all 

correspondence and documents relating to the EOI exchanged by the 

offerer and the EOI Inviting Authority, shall be in English language. 

Supporting documents furnished by the offerer may be written in another 

language provided they are accompanied by an authenticated accurate 

translation of the relevant passages in the English language in which case, 

for purposes of interpretation of the offers, the English translation shall 

govern. 

5.4.4 The offers once submitted will not be altered in any case and should not 

have any scope of ambiguity, cutting or overwriting. In case of overwriting 

/ cutting if any, it must be authenticated with signature of the offerer. 

5.4.5 The documentary evidences submitted along with the EOI shall be 

produced duly attested by the offerer on every page and serially 

numbered. Any interlineations, erasures or over writing shall be valid only 

if they are initialed by the person(s) signing the offer. 

5.4.6 In the event of documentary proof as required being not enclosed, the 

offer shall be liable to be rejected. All pages of the offer shall be signed by 

the authorized person or persons signing the EOI along with the stamp of 

the offerer. 

5.4.7 A copy of the complete EOI document duly signed on every page by the 

offerer or the authorized representative shall be enclosed as part of the EOI 

as a proof of having read and accepted the terms and conditions of the 

EOI document. 

5.4.8 The offer shall be typewritten or written in indelible ink and shall be signed 

by the offerer or person(s) duly authorized to bind the offerer to the 

Contract with Corporation. The letter of authorization, to the satisfaction of 

the Corporation, shall be submitted as by written power-of-attorney 

accompanying the bid / resolution of the board of directors etc. 

5.4.9 An offer submitted in vague/ ambiguous financial terms and the like, shall 

be termed as non-responsive and shall be summarily rejected. 


5.4.10 A prospective offerer requiring any clarification of the EOI documents may 

notify the Corporation in writing by email or fax at the Offer Inviting 

Authority’s mailing address/ fax number indicated in this EOI document. 

The Corporation will respond to any request for clarification of the EOI 

Documents which it receives before 5 days prior to the deadline for 

submission of offer. 

5.4.11 Clarifications to specific requests shall be responded through e-mail and 

general clarifications, affecting all the offerers shall be published in the 

official website of the EOI Inviting Authority. However it shall be the duty 

of the prospective offerer to ensure that the clarifications sought for has 

been properly received in time by the EOI Inviting Authority. 

5.5 Earnest Money Deposit (EMD): 

5.5.1 Non-submission of sufficient EMD as mentioned in Section III along with 

the Technical document shall be one of the primary reasons for rejection of 

the offer in the first round. 

5.5.2 Cheque, Cash payment, Money Order, Fixed deposit etc will not be 

accepted as EMD and in such cases the tender offer will be rejected. 

5.5.3 Laboratories fully owned by the Government / PSUs and reputed Research 

& Development Laboratories attached to scientific / research institutions 

are exempted from remittance of EMD subject to submission of valid 

documents. 

5.5.4 The EMD shall be in one of the following forms: 

A demand draft in favour of Managing Director, Kerala Medical Services 

Corporation Limited, payable at Thiruvananthapuram; 

OR 

A Bank Guarantee issued by a nationalized / scheduled bank located in 

India, in the form prescribed in the tender document (Annexure -III) and 

shall be valid for the period indicated in Section III; Bank Guarantee in any 

other format will not be acceptable and render the bid non-responsive. 

5.5.5 EMD of unsuccessful offerers will be discharged / returned as promptly as 

soon as possible but not later than 30 days after publishing of the final list 

by the Corporation. 

5.5.6 The successful offerer's EMD will be discharged upon the offerer signing 

the contract and furnishing the performance security. The EMD of the 

successful offerer if furnished as demand draft can be adjusted towards the 

security deposit payable. 


5.5.7 No interest will be paid for the EMD submitted. 

5.5.8 The EMD will be forfeited, if an offerer; 

5.5.8.1 Misrepresents facts or submit false / fake documents during the 

EOI process. 

5.5.8.2 If the offerer willfully violates any terms and conditions of the EOI 

documents. 

5.5.8.3 If the offerer withdraws its bid after the opening of EOI 

document. 

5.5.8.4 A successful offerer fails to sign the contract after issuance of 

Letter Of Intent. 

5.5.8.5. Fails to furnish performance security after issuance of Letter Of 

Intent. 

5.5.8.6. If the EOI offer is rejected on the basis of the non satisfactory 

inspection report of the Quality control facilities of the firm. 

5.6 Period of Validity of EOI 

5.6.1 The offers must remain valid for two years. An offer for a shorter period 

shall be rejected by the Corporation as non-responsive. 

5.6.2 Withdrawal or non-compliance of agreed terms and conditions after the 

execution of agreement will lead to invoking of penal provisions and may 

also lead to black listing / debarring of the successful offerer as per the 

procedure detailed in clause 5.34, for a period upto 3 years, immediately 

succeeding the EOI agreement year and the offerer will be ineligible to 

participate in any of the empanelment / tender of the Corporation for a 

period upto 3 year. 

5.7 Pre Offer Meeting 

5.7.1 Date of pre-offer meeting is mentioned in Section III. 

5.7.2 Pre-offer meeting is called by the Corporation to explain briefly about the 

requirements as well as the terms and conditions of the EOI document and 

to get the views of the prospective offerers, as part of ensuring 

transparency in the EOI process. 

5.7.3 It is an opportunity for the prospective offerer to obtain all the details about 

the offered items, conditions governing the offer and also to get the 

explanation of any ambiguous condition that may be present in the EOI 

document. 


5.7.4 It is also an opportunity for the Corporation to assess the market and 

obtain feedback on the current developments in drug testing, so as to 

make amendments in the EOI document on the basis of expert advice. 

5.7.5 All prospective offerers can attend the pre offer meeting. The venue, date 

and time is indicated in Section III. 

5.7.6 Failure to attend the pre-offer meeting will not be a disqualification, but a 

loss of opportunity for the prospective offerers to understand the EOI 

conditions. 

5.7.7 Filled up EOI will be accepted only after the date of pre offer meeting. 

5.8 Amendment of EOI documents: 

5.8.1 At any time prior to the dead line for submission of EOI, the EOI Inviting 

Authority may, for any reason, modify the EOI document by 

amendment. 

5.8.2 The amendment shall be published in the website of the Corporation or 

notified by fax/email to all prospective offerers who have purchased the 

EOI document, for which the email, fax no of the purchaser of the EOI 

document shall be submitted to the EOI inviting authority and such 

amendments, shall be binding on them thereafter. 

5.8.3 The Corporation shall not be responsible for failure to inform the 

prospective offerers because of technical issues, wrong fax number or 

email ID etc. Purchasers of EOI documents are requested to browse the 

website of the Corporation for information / general notices 

/amendments to EOI document etc on a day to day basis till the EOI is 

concluded. 

5.9 EOI Process 

The EOI Process is divided into two: 

5.9.1 Scrutiny of technical documents submitted before the schedule date and 

time. 

5.9.2 Inspection of the shortlisted lab by a technical committee on behalf of the 

Corporation and selection of the lab. 

5.10 Contents of the EOI documents 

5.10.1 The offerer must submit the following documents in a sealed cover 

5.10.2 Checklist (Annexure –I) for the list of documents enclosed with their page 

Nos. The documents should be serially numbered and arranged as per 


Annexure–I and should be securely tied or bound. Non submission of 

any of the documents will result in the rejection of the offer. 

5.10.3 The Earnest Money Deposit, IF NOT EXEMPTED, shall be Rs.25,000/-. 

The Earnest Money Deposit shall be paid in the form of Demand Draft 

favouring Managing Director, Kerala Medical Services Corporation 

Limited, payable at Thiruvananthapuram / bank guarantee (as per 

format attached in Annexure-III) valid for a period of 180 days from the 

date of opening of the technical document. The EMD should be sent with 

the tender form. EMD in the form of Cheque / Cash / Postal Order will 

not be accepted. The EMD will not earn interest. 

5.10.4 Notary Attested Photocopy of approval of Drugs Control Authority for 

testing of Drugs, duly renewed up to date. 

5.10.5 Income tax statement for the last three financial years. 

5.10.6 Notary attested copy of PAN. 

5.10.7 Service Tax Clearance Certificate issued by the concerned authority and 

attested copy of certificate of registration for service tax. 

5.10.8 Notary attested copies of audited Balance Sheet and Profit and Loss 

account for three years i.e. 2009-2010, 2010-2011 and 2011-2012. 

5.10.9 Documentary evidence for Constitution of company/concern such as 

Memorandum and Articles of Association along with notary attested 

copies of Form 32 whenever there is a change of Directors, Latest 

Partnership deed (Notary attested copy) etc. with details of the Name, 

address, Telephone Number, Fax Number, e-mail address of the firm 

and of the Managing Director / Partners / Proprietor. 

5.10.10 Application form with all relevant documents (Annexure – II). 

5.10.11 The list of qualified personnel employed in the laboratory [Annexure-II 

(a)] 

5.10.12 The list of sophisticated instruments available in the laboratory. 

[Annexure II (b)] 

5.10.13 Micro Biological facilities available in the laboratory. [Annexure II (c)] 

5.10.14 List of Reference standards available in the lab. 

5.10.15 Duly filled performance statement in Annexure IV. 

5.10.16 Annual turn over statement certified by the auditors for last three years 

i.e., 2009-2010, 2010-2011 and 2011-2012 as in (Annexure-V) 


5.10.17 Declaration in the Proforma given in Annexure-VI duly signed and 

notarized. 

5.10.18 Details of Laboratory in Annexure–VII. 

5.10.19 Consent letter of the offerer as in Annexure VIII, giving the details of the 

Drug / Items offered to be tested in compliance with the EOI conditions 

and the consent for testing the Drugs / Items at the rates specified in 

Appendix. 

5.10.20 EOI document signed by the offerer in all pages with office seal. 

5.10.21 The offer document should reach the Managing Director, Kerala Medical 

Services Corporation Limited on or before 11 A.M on 27/11/2012. 

5.11 Method of Submission of EOI 

5.11.1 The EOI shall be sent by registered post or by courier to the 

above address or dropped in a box specifically kept at the Head Office 

of Kerala Medical Services Corporation Ltd at Thycaud, 

Thiruvananthapuram -14. 

5.11.2 EOI sent by telex or fax or email is void. 

5.12 Deadline for submission of EOI 

5.12.1 EOI must be received in the office of the Corporation at the address 

mentioned in Clause 2.16 not later than the time and date specified in 

the EOI Schedule (Section III). 

5.12.2 In the event of the specified date for submission of EOI being declared 

holiday, the tender shall be received up to the appointed time on the 

next working day. 

5.12.3 If the EOI is sent by Registered post or by Courier, it should reach the 

above office on or before the time and date stipulated for the receipt of 

EOI. The Corporation shall not be held liable for the delay in transit 

where the EOI is sent by post or courier. 

5.12.4 The Corporation may, at its discretion, extend the deadline for 

submission of EOI by amending the EOI Document, in which case, all 

rights and obligations of the Corporation and the offerers previously 

subjected to the deadline shall thereafter be subjected to the same 

deadline so extended. 


5.13 Modification and Withdrawal of EOI offer 

5.13.1 The offerer may modify or withdraw its offer, after the EOI submission, 

provided that written notice of the modification or withdrawal is received 

by the Corporation before the date opening of the EOI. 

5.13.2 The offerers’ modification or withdrawal notice shall be signed by the 

offerer or his / her authorized representative, who have signed the 

original EOI documents. A withdrawal notice may also be sent by fax or 

email but should necessarily be followed by a signed confirmation copy 

to be received at the head office of the Corporation before the date of 

opening of the technical document. 

5.13.3 No bid may be withdrawn in the interval after the opening of EOI and 

the finalization of the EOI. Withdrawal of an EOI during this interval will 

result in the forfeiture of its EMD and shall lead to black listing of the 

offerer for a period upto 3 years immediately succeeding the offer year 

and the offerer shall be ineligible to participate in any of the offers / 

tenders of the Corporation for a period of 3 years. 

5.14 Opening of EOI 

5.14.1 The opening of the EOI offer shall be done by the Corporation or his 

authorized representative in the presence of the prospective offerers or 

his/her representative who choose to attend at the respective time and 

place mentioned in Section III. 

5.14.2 The offerers or representatives present for the opening of the envelopes 

shall sign registers evidencing their attendances. 

5.14.3 In the event of the specified date for opening of EOI being declared 

holiday, the EOI shall be opened at the appointed time and venue on the 

next working day. 

5.14.4 The offerer’s names, the presence or absence of the requisite EMD and 

such other details as the Corporation may consider appropriate, shall be 

announced at the time of opening of the EOI. 

5.14.5 In the event of the offer and claims in the cover are materially missing or 

of substantial error or unqualified for want of required qualifications, shall 

stand disqualified and rejected. However, minor infirmities in the 

submission of documents will be allowed to be rectified so as to ensure 

qualification of maximum number of offerers to the final round. 

5.14.6 The offerer shall be responsible for properly superscribing and sealing the 

envelopes and the Corporation shall not be held liable for accidental 


opening of the envelopes before the time appointed for opening of the 

offers. 

5.14.7 The final list of eligible empanelled labs will be published only after the 

conclusion of Inspection of laboratory facilities. 

5.14.8 Scanned copies of the key documents such as Approved license, Annual 

turnover statement, NABL accreditation, Details of testing facilities, List 

of Drugs / items other certification offered to be tested submitted by the 

offerers as part of the offer will be published in the website of 

the Corporation immediately after opening of the offer as part of 

transparency of the Corporation. These documents must be submitted in 

CD’s also. 

5.15 Evaluation of EOI 

5.15.1 The documents submitted as part of the offer shall be scrutinized by an 

EOI Evaluation Committee constituted by the EOI Inviting Authority. 

5.15.2 The findings of the Document Evaluation Committee on whether the 

offers are responsive or non-responsive or requiring clarifications will be 

published on the website. 

5.15.3 The inspection of the Drugs testing facilities of those firms which has not 

been inspected during the past years and that of the new participants 

shall be conducted by a team of experts. The check list for inspection 

has been published in the website of the Corporation. 

5.15.4 The list of eligible offerers / rejected offerers as per the findings of the 

decisions of the EOI Evaluation Committee / Inspection team will be 

published in the notice board and website of the EOI Inviting Authority, 

inviting complaints / suggestions from the bidders / public. 

5.15.5 The complaints / suggestions received will be scrutinized by the EOI 

evaluation committee and their findings along with the final list of 

qualified eligible Offerers along with the list of drugs/items approved for 

each lab will be published in the notice board and website. 

5.15.6 An offerer, at any stage of tender process or thereafter, in the event of 

being found after verification by the EOI Inviting Authority, to indulge in 

concealment or misrepresentation of facts, in respect of the claims of the 

offer, shall be debarred/black listed for a period as decided by the EOI 

Inviting Authority. 

5.15.7 The EOI Inviting Authority’s decisions on the offer submitted shall be 

based on the decisions taken by the evaluation and inspection 

committees and otherwise as per the clauses as mentioned above. 


5.15.8 The Corporation may waive any minor infirmity or non-conformity or 

irregularity in an offer, which does not constitute a material deviation, 

provided that the same shall not prejudicially affect the interest of the 

other offerers. 

5.16 Clarification of EOI 

5.16.1 During evaluation of offers, the Corporation may, at its discretion, give 

opportunity to the offerer(s) for clarification of points raised by the EOI 

evaluation committee on its documents submitted. 

5.16.2 The request for clarification and the response shall be in writing, either 

through email or fax or by post. 

5.17 Inspection of Drugs Testing Facilities. 

5.17.1 Inspection of the Drugs Testing facilities will be, by different teams 

consisting of experts from Drugs Control Department / College of 

Pharmaceutical Sciences and Specialists may also be co-opted into the 

team as deemed fit by the EOI Inviting Authority. 

5.17.2 All the expenses incurred for the inspection will be borne by the EOI 

Inviting Authority. 

5.17.3 All the labs including existing labs, if quoting for new products will be 

inspected. 

5.17.4 All the testing sections in the lab will be subjected to rigorous inspection / 

auditing, irrespective of the items quoted. i.e. if the offerer has quoted 

only for tablets in the offer but is having the testing facilities of Injectables 

/ Liquids / Capsules etc. all the sections will be subjected to inspection. 

The offerer will have to provide necessary arrangements to conduct the 

inspection of all the sections and failure to co-operate with the inspection 

in showing the different facilities, in providing information as per the 

check list published in the website will lead to disqualification. 

5.17.5 During inspection undue demands, demands beyond the scope of the 

check list etc made by the members of the Inspection team shall be 

immediately notified to the Corporation by the laboratory by fax, so that 

the disputes could be resolved before the Inspection Team leaves the 

laboratory. The decisions of the Inspection team will not be 

communicated to the offerer at their site and shall be published on the 

website later only. 

5.17.6 Entry to all the areas of testing including microbiological section of the 

lab shall be facilitated. 


5.17.7 The availability of technical experts, analytical facilities as claimed in the 

EOI offer along with the compliance of standard operating procedures 

adapted for each procedure including validation and calibration, shall be 

evaluated by the team for considering the eligibility of the lab. Claim of 

holding the valid NABL certification/valid license will not be accepted for 

eligibility, if the procedures are not followed as per the standard 

operating procedures or if the available facilities are not in working 

condition at the time of inspection, EOI offer will be rejected in such 

cases. 

5.17.8 The minimum number of samples that could be tested at a time will be 

one of the criteria for determining the acceptance/rejection of the lab. 

The Inspection team shall also verify the ability of the offerer in fulfilling 

the requirement of the Corporation. 

5.17.9 Control samples maintained for the batches will be cross checked during 

inspection. Failure to produce any control samples will result in the 

rejection of that product from the EOI offer. 

5.17.10 Copy of one full set of the EOI offer should be made available at the time 

of inspection. 

5.17.11 Originals of all the documents submitted in the EOI offer should be 

produced for verification by the inspection team. Failure to produce any 

of the original documents will result in the rejection of the offer. 

5.17.12 Key testing areas will be photographed by the inspection team. Denial of 

permission for photographing will result in the rejection of EOI offer. 

5.17.13 Failure to observe any of the conditions of the licenses issued under the 

Drugs and Cosmetics Act, by the laboratory, if reported by the inspection 

team will result in the rejection of the EOI offer. 

5.18 Acceptance / Rejection of offers: 

5.18.1 Acceptance /rejection of the EOI offer will be based on the decisions 

taken on the evaluation of the submitted documents and inspection 

report from the expert committee. 

5.18.2 At any point of time, the Corporation reserves the right to cancel or 

modify the EOI of all items of drugs or for any one or more of the items 

of drugs in a tender even after it is awarded to the successful offerer in 

the event the firm deviates from the agreed terms and conditions. 

5.18.3 EOI Inviting Authority, or his authorized representative(s) has the right to 

inspect the labs of offerers, before releasing any samples or at any point 

of time during the continuance of offer and also has the right to reject the 


offer or terminate / cancel the EOI issued and or to re-test, based on 

adverse reports brought out during such inspections. 

5.18.4 The acceptance of the offers will be communicated to the successful 

offerers in writing. 

5.19 Other terms and Conditions 

5.19.1 The offerer shall be responsible for payment of any charges due to any 

statutory authorities such as Income Tax, Sales Tax, and Customs Duties 

etc. In the event, if it is found that there is some statutory deduction to be 

made at the source, the Corporation will have the authority to do so. 

5.20 Notices 

5.20.1 The Corporation shall publish the following information on its website at 

the appropriate time as part of ensuring transparency in the EOI process; 

5.20.2 The offer notices, documents, corrigendum, addendum etc if any. 

5.20.3 Amendments to the EOI conditions, if any, especially after the pre-offer 

meeting. 

5.20.4 Results of the responsiveness of the EOI offer and minor infirmities/ 

clarifications sought. 

5.20.5 List of offerers qualified for Inspection of Drugs Testing facilities and list 

of offerers exempted from such inspection due to the fact that such 

facility was inspected during the previous years. 

5.20.6 Results of the Inspection of Drugs Testing facilities and the list of qualified 

and disqualified firms with reasons for disqualifications. 

5.20.7 Provisional list of eligible offerers with the list of approved products. 

5.20.8 Final list of eligible offerers with the list of approved products. 

5.20.9 The effective date of a notice shall be either the date when delivered to 

the recipient or the effective date specifically mentioned in the notice, 

whichever is later. 

5.21 Award of Contract 

5.21.1 Criteria:-The contract will be awarded to the offerers qualifying to the 

final round after scrutiny of the documents and inspection of Lab 

premises. 


5.22 Notification of Award/Letter of Intent 

5.22.1 The Corporation will notify the successful offerer (s) in writing, by 

registered / speed post or by fax or by email (to be confirmed by 

registered / speed post immediately afterwards) that its offer for testing of 

drug(s), which have been selected by the EOI Inviting Authority, has 

been accepted. This notification is undertaken by issuing a Letter of 

Intent by the EOI Inviting Authority. 

5.22.2 The successful offerer, upon receipt of the Letter of Intent, shall furnish 

the required performance security and submit an agreement in the 

prescribed format as given in Annexure-X within 15 days, failing which 

the EMD will forfeited and the award will be cancelled. 

5.22.3 The Letter of Intent shall constitute the conclusion of the EOI. 

5.23 Signing of Contract 

5. 23.1 The successful offerer shall execute an agreement on a non-judicial 

Kerala Stamp paper of value of Rs.`100/- (stamp duty to be paid by the 

tenderer) within 15 days from the date of the intimation from 

Corporation informing that his offer has been accepted. The Specimen 

format of agreement is available in Annexure-X. 

5. 23.2 If the successful offerer fails to execute the agreement and / or to deposit 

the required security deposit within the time specified or withdraws his 

tender after the intimation of the acceptance of his tender has been sent 

to him or owing to any other reasons, he is unable to undertake the 

contract, his contract will be cancelled and the Earnest Money Deposit 

deposited by him along with his tender shall stand forfeited by the 

Corporation and laboratory shall also be blacklisted as per the procedure 

detailed in clause 5.34, for a period up to three years immediately 

succeeding the EOI year and the offerer will be ineligible to participate in 

any of the offers/tenders of the Corporation for a period of three years. 

5. 23.3 Non performance of any of the EOI provisions will disqualify a firm to 

participate in the tender for a maximum period of three years. 

5. 23.4 The offerer shall not, at any time, assign, sub-let or make over the 

contract or the benefit thereof or any part thereof to any person or 

persons what so ever. 

5. 23.5 Corporation will be at liberty to terminate without assigning any reasons 

thereof the contract either wholly or in part on 30 days notice. The 


offerer will not be entitled for any compensation whatsoever in respect of 

such termination. 

5. 23.6 For infringement of the stipulations of the contract or for other justifiable 

reasons, the contract may be terminated by the EOI Inviting Authority, 

and the offerer shall be liable for all losses sustained by the EOI Inviting 

Authority, in consequence of the termination which may be recovered 

personally from the offerer or from his properties, as per rules. 

5. 23.7 All notices or communications relating to arising out of this agreement or 

any of the terms there of shall be considered duly served on or given to 

the offerer if delivered to him or left at the premises, places of business or 

abode. 

5.24 Performance Security 

5.24.1 There will be a performance security deposit amounting to Rs `50,000 

(Rs Fifty Thousand only) which shall be submitted by the successful 

offerer to the Corporation within 10 days from the date of issuance of 

Letter Of Intent. 

5.24.2 The Security Deposit should be paid upfront along with each contract on 

or before the due date fixed in the Letter Of Intent by Corporation in the 

form of Demand Draft drawn in favour of the Managing Director, Kerala 

Medical Services Corporation Limited payable at Thiruvananthapuram/ 

Bank Guarantee in the format as given in Annexure IX for a period of 30 

months from the date of execution of the agreement. 

5.24.3 Failure of the successful offerer in providing performance security 

mentioned above and/or in executing the agreement in time shall make 

the offerer liable for forfeiture of its EMD and blacklisting of the firm for 3 

years. 

5.24.4 The Performance security shall be denominated in Indian Rupees or in 

the currency of the contract and it shall be in any one of the forms 

namely Account Payee Demand Draft or Bank Guarantee issued by a 

Scheduled bank in India, in the prescribed form as in Annexure IX 

provided in this document endorsed in favour of the EOI Inviting 

Authority valid for a period of 30 months from the date of execution of 

the agreement. 

5.24.5 In the event of any failure / default / deviations from the EOI agreement 

of the successful tenderer with or without any quantifiable loss to the EOI 

Inviting Authority, the amount of the performance security is liable to be 

forfeited. 


5.24.6 Corporation will release the Performance Security without any interest to 

the successful tenderer on completion of the successful tenderers all 

contractual obligations. 

5.24.7 The Bank Guarantee submitted in place of EMD/Security deposit shall be 

in the prescribed formats as in Annexures III and IX to this document. 

Bank Guarantee in no other form will be accepted and will lead to 

rejection of tenders. 

5.24.8 If the successful offerer withdraws from the contract during the period of 

contract, his security deposit will be forfeited, the contract terminated and 

the laboratory shall be blacklisted for a period of three years immediately 

succeeding the EOI year making them ineligible to participate in any of 

the offers / Tender of the Corporation. 

5.25 Testing & Reporting Conditions 

5.25.1 On empanelment and entrustment of the job, the Analytical Laboratory 

should furnish the test reports within. 

1. 15 days of receipt of the sample in case of Tablets, Capsules, 

Pessaries, Ointments, Powder and Liquid Oral Preparations. 

2. 30 days of receipt of the sample in the case of sterile preparations. 

3. The date and time of delivery of samples at the empanelled labs will 

be submitted by the couriers of the Corporation as proof of delivery 

(POD) and shall be obtained by the lab from the Corporation. The 

time period shall be calculated from the date noted in the POD, 

which shall be binding on the empanelled lab. 

5.25.2 Parameters of testing will be as per the QUALITY CONTROL MANNUAL 

modified from time to time published in the website of the Corporation. 

The samples shall pass all the parameters included in the quality control 

manual, failing which the samples will be considered as not of standard 

quality. All the tests mentioned in IP/ BP/ USP/ Drugs & Cosmetics Act. 

Etc., (as the case may be) should be carried out for each and every 

sample. The actual test value obtained after analysis should be clearly 

mentioned in figures. 

5.25.3 Mentioning the words, "COMPLIES" or "PASSES" in the result column of 

the report shall be treated as incomplete report; it is possible to express 

the value of results in figures. 

5.25.4 Every test report must have remarks (i.e.) Standard Quality or Not of 

Standard Quality. 


5.25.5 Reports should be in A4 size paper of good quality. 

5.25.6 Reports should have Sl.No. Description of tests, Specifications & Results 

obtained. 

5.25.7 Reports should be attached along with Spectra / Chromatography data 

sheets if applicable. 

5.25.8 All test reports should be submitted to the KMSCL in triplicate. In case of 

failure of a sample, the result should be communicated immediately to 

the Managing Director through Phone / Fax / E-mail and the report 

should be sent with protocol. 

5.25.9 If in any circumstances (like break down of instrument, non availability of 

reference standard etc.) the Analytical Laboratory is unable to undertake 

analysis for a sample, the same should be reported within 24 hours of 

receipt of such a sample by FAX or E-mail and the sample should be 

returned to the Manager (Quality Control), Kerala Medical Services 

Corporation Limited, Thiruvananthapuram. 

5.25.10 If any sample is received in a damaged condition by the laboratory, the 

sample should not be analyzed and the information should be sent 

immediately to the Manager (Quality Control), Kerala Medical Services 

Corporation Limited, Thiruvananthapuram by FAX or E-mail. 

5.25.11 In the case of Non-Pharmacopoeial Products the Method of Analysis 

should be appended to the Report, especially if the sample happens to 

fail. 

5.25.12 Results to be sent through e-mail followed by signed hardcopy. 

5.26 Payment Provisions 

5.26.1 No advance payments towards Analysis of drugs will be made to the 

Lab. 

5.26.2 Payments towards the Analysis of drugs will be made strictly as per terms 

and conditions laid down in the EOI document and the decisions of the 

EOI Inviting Authority. All payments will be made only by way of 

electronic fund transfer in favour of the laboratory for which the bank 

details shall be furnished to the Corporation at the time of entering into 

agreement. 

5.26.3 The laboratory shall resist from deputing their representatives to the head 

office of the Corporation for follow up for payments as the Corporation 

has a system of publishing the status of payments in respect of invoices 

submitted to it on 10 th of every month. All the communication in this 


egard shall be in writing and the Corporation discourages the visits, 

phone calls etc as part of transparency. 

5.26.4 All bills / Invoices in triplicate is to be submitted directly to the 

Headquarters. 

5.26.5 If at any time during the period of contract, the testing fee of any items is 

reduced by the offerer himself or the taxes levied is brought down by any 

law or Act of the Central or State Government the offerer shall be bound 

to inform Corporation immediately about such reduction in the 

contracted prices. EOI Inviting Authority is empowered to unilaterally 

effect such reduction as is necessary in rates in case the offerer fails to 

notify or fails to agree for such reduction of rates. 

5.27 Deduction in Payments & Penalties 

5.27.1 All reporting should be made within the stipulated time as mentioned in 

clause 4.1. 

Category of Drug 

Tablet 

Capsule 

Pessaries 

Ointments & creams 

Powder 

Time Permitted 

from the date of 

receipt of sample 

Penalty for delayed 

reporting 


15 

Liquid oral 

Preparation 

All sterile preparations 30 

@ 0.5% per day of 

the delayed reporting 

upto a max of 15% 

5.27.2 In all the above conditions, the decision of the Corporation shall be final 

and binding. 

5.28 Saving Clause 

5.28.1 No suit, prosecution or any legal proceedings shall lie against 

Corporation or any person for anything that is done in good faith or 

intended to be done in pursuance of tender. 

5.29 Applicable Law & Jurisdiction of Courts

5.29.1 The contract shall be governed by and interpreted in accordance with the 

laws of India for the time being in force. 

5.29.2 Any and all disputes arising out of this EOI will be subject only to the 

jurisdiction of courts of law / tribunals situated in Thiruvananthapuram 

city or normally having territorial jurisdiction over Thiruvananthapuram 

city only or the High Court of Kerala as applicable. It is possible that 

jurisdiction to file disputes may available before courts of law, including 

High Courts / Tribunals situated elsewhere. However, considering the 

limited resources of the Corporation, the offerers should specifically agree 

and covenant not to file any legal proceedings before any such courts of 

law / tribunal and should undertake and bind themselves to initiate and 

carry on legal proceedings in respect of this EOI exclusively before the 

Courts of law /Tribunals situated in or normally having territorial 

jurisdiction over Thiruvananthapuram city, or the high Court of Kerala as 

applicable. Any offerer who violates these conditions will be held to have 

indulged in an unacceptable / unfair practice and will be deemed 

ineligible to participate in any of the offers/tenders of the Corporation for 

a period of two years from the date of the breach/violation of the 

aforesaid conditions. 

5.29.3 The offerers are also required to abstain from printing the words“ subject 

to jurisdiction of Delhi Courts only’ etc from on the invoices submitted, 

which may force the Corporation to entertain the payment only after the 

offerer undertakes in writing his/ her agreeing to the conditions above in 

respect of the jurisdiction of the courts of Kerala. 

5.30 Corrupt or Fraudulent Practices 

5.30.1 It is required by all concerned namely the offerers / Successful offerers etc 

to observe the highest standard of ethics during the process and 

execution of such contracts. In pursuance of this policy, the Corporation 

defines, for the purposes of this provision, the terms set forth below as 

follows: 

5.30.2 “Corrupt practice” means the offering, giving, receiving or soliciting of 

anything of value to influence the action of a public official in the Quality 

control process or in contract execution; and 

5.30.3 “Fraudulent practice” means a misrepresentation of facts in order to 

influence a procurement process or the execution of a contract to the 

detriment of the EOI Inviting Authority, and includes collusive practice 

among offerers (prior to or after EOI submission) designed to establish 


testing fees at artificial non-competitive levels and to deprive the 

Corporation of the benefits of fair offer. 

5.30.4 Government/ Corporation will reject a proposal for award if it determines 

that the offerer recommended for award has engaged in corrupt or 

fraudulent practices in fixing the testing fee; will declare a lab ineligible, 

either indefinitely or for a stated period of time, to be awarded a contract 

by the Corporation if it at any time determines that the lab has engaged 

in corrupt or fraudulent practices in fixing the testing fee, or in executing 

the contract. 

5.30.5 No offerer shall contact the Corporation or any of its officers or any 

officers of the Government on any matter relating to its offer, other than 

communications for clarifications and requirements under this EOI in 

writing, with an intention to influence the members of various 

committees or officials of EOI Inviting Authority. Any such effort by an 

offerer to influence the Corporation in the EOI Inviting Authority’s 

evaluation committee, or contract award decisions may result in rejection 

of the EOI offer. 

5.30.6 The offerer shall not be in any way interested in or concerned directly or 

indirectly with, any of the officers, subordinates or servants of the 

Corporation in any trade or business or transactions nor shall the offerer 

give or pay promise to give or pay any such officers, subordinates or 

servants directly or indirectly any money or fee or other considerations 

under designation of “Custom” or otherwise, nor shall the offerer permit 

any person or persons whom so ever to interfere in the management or 

performance hereof under the power of attorney or otherwise without the 

prior consent in writing of the EOI Inviting Authority. Any such effort by 

the offerer to influence the Corporation or its officers may result in 

rejection of the EOI offer. 

5.30.7 If it is revealed that the analytical Laboratory is involved in any form of 

fraud and collusion with the suppliers of Kerala Medical Services 

Corporation Limited, the Analytical Laboratory will be blacklisted for a 

period of 5 years. The tenderers shall also be liable for action under 

criminal law and the matter will be notified to the concerned Director of 

Drugs Control for penal action against them. 

5.31 Force Majeure 

5.31.1 For purposes of this clause, Force Majeure means an event beyond the 

control of the successful offerer and not involving the successful offerers 

fault or negligence and which is not foreseeable and not brought about at 


the instance of, the party claiming to be affected by such event and 

which has caused the non – performance or delay in performance. Such 

events may include, but are not restricted to, acts of the Corporation 

either in its sovereign or contractual capacity, wars or revolutions, 

hostility, acts of public enemy, civil commotion, sabotage, fires, floods, 

explosions, epidemics, quarantine restrictions, strikes excluding by its 

employees, lockouts excluding by its management, and freight 

embargoes, Scarcity of reagents and power cut are considered as force 

majeure. 

5.31.2 If a Force Majeure situation arises, the successful offerer shall promptly 

notify the Corporation in writing of such conditions and the cause thereof 

within ten days of occurrence of such event. The time for completing the 

reporting may be extended by the Corporation at its discretion for such 

period as may be considered reasonable. 

5.31.3 In case due to a Force Majeure event the Corporation is unable to fulfill 

its contractual commitment and responsibility, the Corporation will notify 

the successful offerer accordingly and subsequent actions taken on 

similar lines described in above sub-paragraphs. 

5.32 Resolution of disputes 

5.32.1 If dispute or difference of any kind shall arise between the Corporation 

and the successful offerer in connection with or relating to the contract, 

the parties shall make every effort to resolve the same amicably by 

mutual consultations. 

5.32.2 If the parties fail to resolve their dispute or difference by such mutual 

consultation within twenty-one days of its occurrence, then, unless 

otherwise provided in the EOI document, either the Corporation or the 

successful offerer may give notice to the other party of its intention to 

commence arbitration, as provided the applicable arbitration procedure 

will be as per the Arbitration and Conciliation Act, 1996 of India. 

5.32.3 In the case of a dispute or difference arising between the Corporation 

and a domestic Successful offerer relating to any matter arising out of or 

connected with the contract, such dispute or difference shall be referred 

to the sole arbitration of Secretary to Health, Govt. of Kerala whose 

decision shall be final. 

5.32.4 Venue of Arbitration: The venue of arbitration shall be the 

place from where the contract has been issued, i.e., 

Thiruvananthapuram, India. 

5.33 General / Miscellaneous Clauses 


5.33.1 Nothing contained in this Contract shall be constructed as establishing or 

creating between the parties, i.e. the Successful offerer on the one side 

and the Corporation on the other side, a relationship of master and 

servant or principal and agent. 

5.33.2 Any failure on the part of any Party to exercise right or power under this 

Contract shall not operate as waiver thereof. 

5.33.3 The Successful offerer shall, at all times, indemnify and keep indemnified 

the Corporation any claims in respect of any damages or compensation 

payable in consequences of any accident or injury sustained or suffered 

by its employees or agents or by any other third party resulting from or 

by any action, omission or operation conducted by or on behalf of the 

successful offerer. 

5.33.4 All claims regarding indemnity shall survive the termination or expiry of 

the contract. 

5.34 Procedure for Blacklisting 

5.34.1 For blacklisting a laboratory for defaulted reporting, a registered notice 

shall be issued to the laboratory calling for explanation within 7 days 

from the date of receipt of notice. On receipt of the explanation from the 

Laboratory, the Corporation and Managing Director, may take 

appropriate action on merits of the case and impose blacklisting of the 

particular laboratory by passing appropriate orders. 

5.35 Provisions for Appeal 

5.35.1 A laboratory which has been blacklisted by the Corporation may, within 

15 days from the date of receipt of such order, appeal to the State 

Government. The State Government after such enquiry into the matter, 

as is considered necessary and after giving the said supplier an 

opportunity for representing his views, may pass such order in relation 

thereto as it thinks fit. 

5.36 Termination of Contract 

5.36.1 Termination for default:- The Corporation without prejudice to any other 

contractual rights and remedies available to it (the EOI Inviting 

Authority), may, by written notice of default sent to the successful offerer, 

terminate the contract in whole or in part, if the successful offerer fails to 

deliver any or all of the goods or fails to perform any other contractual 

obligation(s) within the time period specified in the contract, or within 

any extension thereof granted by the EOI Inviting Authority. 


5.36.2 Unless otherwise instructed by the EOI Inviting Authority, the successful 

tenderer shall continue to perform the contract to the extent not 

terminated. 

5.36.3 Termination for insolvency: If the successful offerer becomes bankrupt or 

otherwise insolvent, the Corporation reserves the right to terminate the 

contract at any time, by serving written notice to the successful offerer 

without any compensation, whatsoever, to the successful offerer, subject 

to further condition that such termination will not prejudice or affect the 

rights and remedies which have accrued and / or will accrue thereafter to 

the EOI Inviting Authority. 

5.36.4 Termination for convenience: - The Corporation reserves the right to 

terminate the contract, in whole or in part for its (EOI Inviting 

Authority’s) convenience, by serving written notice on the successful 

tenderer at any time during the currency of the contract. The notice shall 

specify that the termination is for the convenience of the EOI Inviting 

Authority. The notice shall also indicate interalia, the extent to which the 

successful offerers performance under the contract is terminated, and the 

date with effect from which such termination will become effective. 

Managing Director, KMSCL 

& 

(EOI Inviting Authority) 


ANNEXURES 


CHECK LIST 

ANNEXURE-I 

Ref. Clause No.5.10.2 

Name of the Laboratory : ____________________________________ 

Address : ____________________________________ 

____________________________________ 

Sl. 

No: 

1. Checklist –Annexure I 

List of Enclosures Page 

No: 

2. Annexure II- Application Form 

3. Annexure II (a)- Personnel in QC 

Dept. 

4. Annexure II (b) – List of sophisticated 

drugs analytical equipments/apparatus 

available in the laboratory 

5. Annexure II (c) – Facilities in the 

microbiological section 

6. Annexure-III- EMD 

7. Annexure-IV - Performa for 

Performance Statement 

8. Annexure V - Annual turn over for the 

last three years. 

9. NABL Certification 

10. WHO, GLP, UNICEF, ISO certificates 

if any 

11. Annexure VI - Declaration 

Remarks 


EOI Cost 

EMD 

12. Annexure VII - Details of Laboratory 

13. Annexure VIII – Offer Letter 

14. Notary attested copy of License 

15. EOI document signed and sealed 

DD / Receipt with date Amount Validity Name of 

bank 

DD/BG No: with date Amount 

Validity Name of 

bank 


APPLICATION FORM 

ANNEXURE – II 

Ref.Clause No.5.10.10 

[Note: - The following details filled in this form must be accompanied by sufficient 

documentary evidence, in order to verify the authenticity and correctness of the 

information.] 

Sl.No. Particulars Details (To be filled in by the EOI Responder) 

1 Name of the Organization 

Address(Regd. Office): 

Telephone: 

Fax: 

E-mail: 

Website: 

2 Name of the Contact 

Person: 

Telephone: 

Mobile: 

E-mail ID: 

3 Type of the Organization 

(Public Sector/Limited/ 

Private Limited/Partnership/ 

Proprietary/Any Other): 

4 Chief Officer of the 

Organization: 

E-mail ID: 

Telephone: 

5 Registration No. & Date of 

Incorporation of Company: 

6 License No. & Date for 

conducting the Analysis. 

7 PAN no: 

8 Activities of the organization: 

(Briefly List) 

9 List of 3 Clients as per clause 


No.4.2.8 

(Provide contact details like 

Address, Contact Person, 

e-mail ID, Telephone) 

10 Total No. of Employees: 

1. Technical Staff 

2. Non-Technical Staff 

(Details of qualified 

personnels for testing 

of drugs) 

11 List of drugs being tested by 

the organization 

12 Whether the License of the 

Company was cancelled / 

suspended by the authority 

in the past, if yes give 

details. 

13 Whether any prosecution 

was filed or pending against 

the company or any of its 

promoters in the past. 

Declaration 

I hereby declare that the above mentioned statements are true to the best of 

my knowledge and belief. 

Date: Seal: Authorized 

Signatory: 


PERSONNEL IN QC DEPARTMENT 

ANNEXURE- II (a) 



Address : ____________________________________ 

____________________________________ 

Name of the Staff Designation 

Signature : 

Date : 

Name of the Lab : 

Office Seal : 

Highest 

Qualification 

Experience (relevant to 

analysis of 

drugs/surgical/sutures) 


ANNEXURE- II (b) 


LIST OF SOPHISTICATED ANALYTICAL DRUGS EQUIPMENTS / 

APPARATUS AVAILABLE IN THE LABORATORY 


Address : ____________________________________ 

____________________________________ 

Name of the 

Equipment/ 

Instruments/Apparatus 

Signature : 


Date : 

Name & Description Date of 

Installation 

Working 

Conditions 

ANNEXURE- II (c) 



FACILITIES IN THE MICROBIOLOGICAL SECTION 


Address : ____________________________________ 

____________________________________ 

I. List of Stock Cultures Available 

II. List of Equipments / Apparatus Available with Date of Installation 

(Eg. Incubators, Autoclave etc.) 

Signature : 

Name of the lab : 

Date : 


ANNEXURE-III 


FORMAT OF BANK GUARANTEE OF EARNEST MONEY DEPOSIT 

To 

The Kerala Medical Services Corporation Limited 

(Address) 

WHEREAS _____________________________ (Name and address of the 

Laboratory) (Hereinafter called “the laboratory”) has undertaken, in pursuance of 

EOI no________________________ dated _____________ (herein after called “the 

EOI”) to participate in the EOI process of The Kerala Medical Services Corporation 

Limited, (address). 

AND WHEREAS it has been stipulated by you in the said EOI that the laboratory 

shall furnish you with a bank guarantee by a scheduled commercial bank recognised 

by you for the sum specified therein as Earnest Money Deposit for compliance with 

its obligations in accordance with the EOI document; 

AND WHEREAS we have agreed to give the laboratory -----------------(name and 

address) such a bank guarantee; 

NOW THEREFORE we hereby affirm that we are guarantors and responsible to you, 

on behalf of the laboratory, up to a total amount of ________________________ 

(Amount of the guarantee in words and figures), and we undertake to pay you, upon 

your first written demand declaring the bidder to be in default under the EOI 

conditions and without cavil or argument, any sum or sums within the limits of 

(amount of guarantee) as aforesaid, without your needing to prove or to show 

grounds or reasons for your demand or the sum specified therein. 

We hereby waive the necessity of your demanding the said debt from the laboratory 

before presenting us with the demand. 

We undertake to pay you any money so demanded notwithstanding any dispute or 

disputes raised by the laboratory(s) in any suit or proceeding pending before any 

Court or Tribunal relating thereto our liability under these presents being absolute 

and unequivocal. 

We agree that no change or addition to or other modification of the terms of the EOI 

to be performed there under or of any of the EOI documents which may be made 

between you and the laboratory shall in any way release us from any liability under 


this guarantee and we hereby waive notice of any such change, addition or 

modification. 

No action, event, or condition that by any applicable law should operate to discharge 

us from liability, hereunder shall have any effect and we hereby waive any right we 

may have to apply such law, so that in all respects our liability hereunder shall be 

irrevocable and except as stated herein, unconditional in all respects. 

This guarantee will not be discharged due to the change in the constitution of the 

Bank or the laboratory(s). 

We, ________________________________________ (indicate the name of bank) 

lastly undertake not to revoke this guarantee during its currency except with the 

previous consent, in writing, of The Kerala Medical Services Corporation Limited. 

This Guarantee will remain in force up to -------- (Date). Unless a claim or a demand 

in writing is made against the bank in terms of this guarantee on or before the expiry 

of ------(Date) all your rights in the said guarantee shall be forfeited and we shall be 

relieved and discharged from all the liability there under irrespective of whether the 

original guarantee is received by us or not. 

(Signature with date of the authorised officer of the Bank) 

…………………………………………………………. 

Name and designation of the officer 

…………………………………………………………. 

…………………………………………………………. 

Seal, name & address of the Bank and address of the Branch 

ANNEXURE- IV 


PROFORMA FOR PERFORMANCE STATEMENT 

(for a period of last 3 years) 



Address : ____________________________________ 

Types of Samples Analyzed 

1 Tablets / Capsules / Pessaries 

2 Injectable 

3 Liquid Orals 

4 Ointments / Creams / Gels 

5 Others (drugs and supplies) 

6 

Surgicals (Specify item 

names) 

7 Sutures (Specify types) 

Signature : 

Date : 


Office Seal : 

____________________________________ 

No. of Samples Analyzed during 

2009-2010 2010-2011 2011-2012 


ANNUAL TURN OVER STATEMENT 

ANNEXURE- V 


The annual Turnover of M/s………………………… …………………… for the past 

three years are given below and certified that the statement is true and correct. 

Sl.no: year Turnover 

1 2009-2010 

2 2010-2011 

3 2011-2012 

Total Rs …………..lakhs 

Average annual turnover - Rs…………….Lakhs 

Date: Signature of auditor/ 

Chartered Accountant 

(Name in capital) 

Seal: 


DECLARATION FORM 

ANNEXURE-VI 


I / We ………………………………………………………………… (Name of 

the laboratory) having our office at 

……………………………………………………………………………………………… 

……………………………………………………………………………………… Lab at 

……………………………………………………………………………………………… 

…..………………………………….. do declare that I / We have carefully read all the 

conditions of EOI document of Kerala Medical Services Corporation Ltd., 

Thiruvananthapuram, for the EOI floated for empanelment of analytical testing 

laboratories for the analysis of drugs / surgical / sutures etc., for a period of two years 

from the date of acceptance and abide by all conditions set forth therein. 

I / We further declare that I / We posses valid License bearing No. 

………………………………………………………………………………. valid upto. 

……………………………………….. 

Signature : 

Date : 


Office Seal : 

ATTESTED BY NOTARY PUBLIC 


DETAILS OF LABORATORY 

Name of the Laboratory : 

Full Address : 

Registration details : 

Place of business : 

Phone No : 

Fax : 

E-mail : 

Branches & their Address : 

Date of Inspection : 

License No. & Date : 

Issued by : 

Valid up to : 

Details of testing activity : 

Clients List : 

Name of the authorized signatory : 

Specimen Signature of the authorized 

Signatory : 

Specimen Signature of the officer who 

is authorized to sign the test reports : 

ANNEXURE-VII 


ANNEXURE-VIII 


CONSENT LETTER OF THE OFFERER 

From, 

Name of the Laboratory, 

Address of the Laboratory 

To, 

The EOI Inviting Authority 

Sir, 

Subject-Consent for testing of Drugs/Items 

Reference-KMSCL/QC/EOI/FY12-14/02 


With reference to your EOI document, we here by submit our consent to test the 

following items of drugs at the rates specified in Annexure-VIII and as per the 

conditions stipulated in the EOI documents referred above. 

Sl.No. Drug Code 

Name of the Drug with 

specifications 

Rate 

S/d 

(Name of the Offerer) 


FORMAT OF BANK GUARANTEE FOR SECURITY DEPOSIT 

To 

The Kerala Medical Services Corporation Limited 

(Address) 

ANNEXURE-IX 

Refer Clause No.5.24.2 

WHEREAS _____________________________ (Name and address of the 

Laboratory) has undertaken, in pursuance of contract no________________________ 

dated _____________ (herein after called “the contract”) to conduct quality control 

analysis for Kerala Medical Services Corporation Limited, (address). 

AND WHEREAS it has been stipulated by you in the said contract that the 

Laboratory shall furnish you with a bank guarantee by a scheduled commercial bank 

recognised by you for the sum specified therein as security for compliance with its 

obligations in accordance with the contract; 

AND WHEREAS we have agreed to give the Laboratory such a bank guarantee; 

NOW THEREFORE we hereby affirm that we are guarantors and responsible to you, 

on behalf of the Laboratory, up to a total amount of ________________________ 

(Amount of the guarantee in words and figures), and we undertake to pay you, upon 

your first written demand declaring the Laboratory to be in default under the contract 

and without cavil or argument, any sum or sums within the limits of (amount of 

guarantee) as aforesaid, without your needing to prove or to show grounds or 

reasons for your demand or the sum specified therein. 

We hereby waive the necessity of your demanding the said debt from the Laboratory 

before presenting us with the demand. 

We undertake to pay you any money so demanded notwithstanding any dispute or 

disputes raised by the Laboratory (s) in any suit or proceeding pending before any 

Court or Tribunal relating thereto our liability under these presents being absolute 

and unequivocal. 

We agree that no change or addition to or other modification of the terms of the 

contract to be performed there under or of any of the contract documents which may 

be made between you and the Laboratory shall in any way release us from any 


liability under this guarantee and we hereby waive notice of any such change, 

addition or modification. 

No action, event, or condition that by any applicable law should operate to discharge 

us from liability, hereunder shall have any effect and we hereby waive any right we 

may have to apply such law, so that in all respects our liability hereunder shall be 

irrevocable and except as stated herein, unconditional in all respects. 

This guarantee will not be discharged due to the change in the constitution of the 

Bank or the Laboratory (s). 

We, ________________________________________ (indicate the name of bank) 

lastly undertake not to revoke this guarantee during its currency except with the 

previous consent, in writing, of The Kerala Medical Services Corporation Limited. 

This Guarantee will remain in force up to---------- (Date). Unless a claim or a demand 

in writing is made against the bank in terms of this guarantee on or before the expiry 

of ------------- (Date) all your rights in the said guarantee shall be forfeited and we 

shall be relieved and discharged from all the liability there under irrespective of 

whether the original guarantee is received by us or not. 

(Signature with date of the authorised officer of the Bank) 

…………………………………………………………. 

Name and designation of the officer 

…………………………………………………………. 

…………………………………………………………. 

Seal, name & address of the Bank and address of the Branch 

ANNEXURE-X 


AGREEMENT 

Ref. Clause No. 5.23.1 

THIS AGREEMENT made on this ………………… day of ……………, 20… 

between ………………………………….. Kerala Medical Services Corporation Ltd 

represented by its Managing Director having its registered office at 

Thiruvananthapuram (hereinafter called as “The KMSCL”) of one part and M/s. 

……………………………………………………………………………………………… 

…………………………………………………………………………… (Name and 

Address of the laboratory)(hereinafter called as “The laboratory”) represented by 

…………………………………………………………………………. (Name of the 

authorized signatory and Designation), aged …………. Years, residing at 

………………………………………. (Full residential address of the signatory) of the 

other part. 

Whereas the Laboratory has offered to the KMSCL to undertake analytical 

work of the list of items mentioned in the Annexure-I attached hereto, at the rates 

noted therein and in the manner and under the terms and conditions hereinafter 

mentioned and the KMSCL has accepted the offer. 


And whereas the Laboratory has deposited with the KMSCL a sum of 

Rs.50,000/-(Rupees Fifty Thousand) as Security Deposit for the due and faithful 

performance of this Agreement, to be forfeited as liquidated damages in the event of 

the Laboratory failing duly and faithfully to perform its obligations set forth 

hereinafter. 

In this agreement words and expressions shall have the same meanings as are 

respectively assigned to them in the tender document referred to. 

Now therefore these presents witness that for carrying out the said Agreement 

in this behalf into execution, the Laboratory and the KMSCL do hereby mutually 

covenant ,declare, contract and agree each of them with the other of them in the 

manner following, that is to say, 

1. The term “Agreement”, wherever used in this connection, shall mean the terms 

and conditions stipulated hereinafter for the analysis of Drugs, surgical items and 

Sutures for the year 2012-2014. 

2. (a) The agreement is for undertaking analysis of Drugs, Surgical items & Sutures 

items by the Laboratory to the KMSCL of the samples specified in the 

…………………. (will specify later) attached hereto at the rates noted against each 

therein on the terms and conditions set forth in this Agreement and strictly within the 

time frame stipulated for the respective items in clause 4.1 of the EOI document. 

(b) This agreement shall be deemed to have come into force with effect from ---------- 

----------- (Date of execution of agreement) and it shall remain in force for a period of 

2 years with effect from that date and may however be extended for a further period, 

on mutually agreed terms signed by both parties. 

(c) The time frame specified in clause 4.1 of the EOI document for the respective 

item shall be strictly adhered to by the Laboratory and the test reports should reach 

the KMSCL within the maximum time allowed therein reckoned from the date on 

which the item to be tested is delivered to the Laboratory. 

(d) The test reports are to be submitted to the KMSCL by email within the time 

period specified in clause 4.1 of the EOI document at the email address of the 

KMSCL (kmsclqcresults@gmail.com) to be followed by three sets of hardcopies duly 

authenticated. 


(e) In the event of any failure/default/deviations from the EOI agreement of the 

successful tenderer with or without any quantifiable loss to the KMSCL, the amount 

of the performance security is liable to be forfeited. If the successful laboratory 

withdraws from the contract during the period of contract, his security deposit will be 

forfeited, the contract terminated and the laboratory shall be blacklisted for a period 

of three years immediately succeeding the EOI year making them ineligible to 

participate in any of the offers/Tender of the corporation. 

INSPECTION OF LABORATORY 

3. In respect of the analysis of items in the Schedule, the laboratory shall allow 

inspection of the laboratory at any time during the continuance of the contract period 

by a team of Experts/Officials whom the KMSCL may depute for the purpose. The 

laboratory shall extend all facilities to the team to enable them to inspect sample 

storage, reagents, instruments, all relevant records, analysis etc, in the laboratory. 

RECOVERY OF MONEYS DUE TO THE KMSCL FROM LABORATORY 

4.All expenses, damages and other moneys payable to the KMSCL by the laboratory 

under any provisions of this Agreement may be recovered from the amounts due or 

subsequently becoming due from the KMSCL to the laboratory under this or any 

other Agreement. In case such amount are insufficient to fully cover such expenses, 

damages or other moneys payable. It shall be lawful for the KMSCL to recover the 

balance amount from the security deposit of the laboratory and all other money held 

by KMSCL and in case such security deposit is insufficient then it shall be also be 

lawful for the KMSCL to recover the residue of the set expenses, damages and 

moneys. If necessary by resorting to legal proceeding against the laboratory. 

5. The amount of security deposit shall be remitted by the laboratory to the KMSCL 

by way of Demand Draft by favoring the Managing Director, KMSCL, 

Thiruvananthapuram. The amount will be returned on successful fulfillment of the 

terms and conditions of this agreement without any interest. 

SUBMISSION OF BILLS FOR UNDERTAKING ANALYSIS 

6. (a) No advance payment towards any analysis will be made to the laboratory. 

(b) All bills/invoices should be raised in triplicate in the name of the managing 

director Kerala Medical Services Corporation Limited. All payments will be 

made only by way of electronic fund transfer in favour of the Laboratory for 


which bank details shall be furnished to the Corporation at the time of entering 

into agreement. 

(c) All the empanelled analytical laboratories should furnish the test reports 

within: 

I. 15 days of receipt of the samples in case of Tablets, Capsules, Pessaries, 

Ointments, Powders and Liquid Oral Preparations. 

II. 30 days of receipt of the samples in the case of all other sterile 

preparations. 

(d) If a lab fails to submit the report of analysis with in the above stipulated 

period penality of 0.5% per day of the delayed reporting up to a maximum of 

15% on the value of testing will be levied. 

ASSIGNMENT OF CONTRACT PROHIBITED 

7. The laboratory shall not at anytime assign, sub-let or make over the present 

Contract or the benefits thereof or any part thereof, to any person or persons 

whomsoever. 

TERMINATION OF CONTRACT ON BREACH OF CONDITION 

8. (a) In case the laboratory fails of neglects or refuses to faithfully perform any of the 

covenants on his part herein contained or violates the EOI condition in EOI 

document, it shall be lawful for the KMSCL to forfeit the amount deposited by the 

laboratory as security deposit and cancel the contract, apart from black listing the 

laboratory for a period of three years. 

(b) The successful laboratory shall, at all times, indemnify and keep indemnified the 

Corporation any claims in respect of any damages or compensation payable. In 

consequences of any accident or injury sustained or suffered by its employees or 

agents or by any other third party resulting from or by any action, omission or 

operation conducted by or on behalf of the successful laboratory. 

(c). The KMSCL reserves the right to terminate without assigning any reasons 

therefore the contract / agreement either wholly or in part with out any notice to the 

laboratory. The laboratory will not be entitled for any compensation whatsoever in 

respect of such termination of the Contract/agreement by the KMSCL. 


NOTICES ETC. IN WRITING 

9.All certificates or Notices or orders for time or for extra, varied or altered laboratory 

which are to be the subject of extra or varied charges whether so described in the 

agreement or not, shall be in writing and unless in writing, shall not be valid, binding 

or be of any effect whatsoever. 

LABORATORIES NOT TO HAVE ANY INTEREST IN THE OFFICERS 

CONCERNED AND SUBORDINATES 

10. The laboratory shall not be in any way interested in or concerned directly or 

indirectly with, any of the officers, subordinates or servants of the Corporation in any 

trade or business or transactions nor shall the laboratory give or pay promise to give 

or pay any such officers, subordinates or servants directly or indirectly any money or 

fee or other considerations under designation of “Custom” or otherwise, nor shall the 

laboratory permit any person or persons whom so ever to interfere in the 

management or performance hereof under the power of attorney or otherwise 

without the prior consent in writing of the KMSCL. Any such effort by the laboratory 

to influence the Corporation or its officers may result in rejection of the Agreement. 

BANKRUPTCY OF THE LABORATORY 

11. Termination for insolvency: If the successful laboratory becomes bankrupt or 

otherwise insolvent, the Corporation reserves the right to terminate the contract at 

any time, by serving written notice to the successful laboratory without any 

compensation, whatsoever, to the successful laboratory, subject to further condition 

that such termination will not prejudice or affect the rights and remedies which have 

accrued and / or will accrue thereafter to the KMSCL. 

SERVING OF NOTICES ON LABORATORY 

12. All notices of communications relating to or arising out of this agreement or any 

of the terms thereof shall be considered duly served on or give to the laboratory if 

delivered to it or left at his address or, place of business as above. 

13. And it is hereby agreed and declared between the parties hereto that in case any 

question of dispute arised touching the construction or wording of any clause herein 

contained on the rights, duties, liabilities of the parties hereto or any other way, 

touching or arising out of the presents, the decision of the Managing Director, Kerala 

Medical Services Corporation Limited, in the matter shall be final and binding. 


14. In the event of any disputes between the parties, the dispute would be subjected 

to the jurisdiction of courts of law / tribunals situated in Thiruvananthapuram city or 

normally having territorial jurisdiction over Thiruvananthapuram city only or the 

High Court of Kerala as applicable. It is possible that jurisdiction to file disputes may 

available before courts of law, including High Courts / Tribunals situated elsewhere. 

However, considering the limited resources of the Corporation, the offerers should 

specifically agree and covenant not to file any legal proceedings before any such 

courts of law / tribunal and should undertake and bind themselves to initiate and 

carry on legal proceedings in respect of this EOI exclusively before the courts of law 

/tribunals situated in or normally having territorial jurisdiction over 

Thiruvananthapuram city, or the high Court of Kerala as applicable. 

In witness whereof the parties hereto have caused this Agreement to be executed in 

accordance with their respective laws the day and year first above written. 

Signed, Sealed and Delivered by the 

said ………………….............. (For the KMSCL) 

in the presence of, 

1. ………………………………….. (Signature, name and Address) 


Signed, Sealed and Delivered by the 

said ………………….............. (For the Laboratory) (Signature, Name and Address 

with Office Seal) 

in the presence of, 



Appendix 

Ref Clause No. 5.10.19 

DETAILS OF LABRATES FOR THE DRUGS 

CATEGORY I 

Sl Drug Drug Name Dosage Strength RATE REMARKS 


No Code form 

1 D01019 Aceclofenac Tab. 100mg 550 

2 D13024 Acetylsalicylic Acid 

IP 

Tab. 75mg 380 

3 D09003 Acyclovir BP Cream 5% w/w 683 

4 D09001 Acyclovir IP Inj. 250 mg 683 

5 D09002/ 

12 

Acyclovir IP Tab. 400 mg 683 

6 D05005 Adrenaline Bitartrate Inj. 1mg/ml 1450 

7 D08015 Albendazole Suspension 200 mg/5ml 380 

8 D08001 Albendazole Tab. 400 mg 418 

9 D17007/ 

12 

Alprazolam Tab. 0.25mg 531 

10 D20003/ Aluminium Tab. 500 mg (Chewable with 357 

12 Hydroxide 

flavour ) 

11 D02021 Amikacin Sulphate Inj IP 250mg/ml 683 

12 D03003 Aminophylline Inj I.P. 25mg/ml 584 

13 D17005 AmitrIPtyline Tab I.P. 25mg 607 

14 D13031/ 

12 

AmlodIPine Tab 5 mg (film coated) 987 

15 D13012/ 

12 

AmlodIPine Tab 2.5 mg (film coated) 987 

16 D02036/ Amoxicillin + Tab. 500+ 125mg 600 

12 Clavulanic Acid 

17 D02004 Amoxycillin Cap IP 250 mg 455 

18 D02005 Amoxycillin Cap IP 500 mg 455 

19 D02032 Amoxycillin Dry Syrup 125 mg/5ml 805 

20 D02041 Ampicillin Cap. 500mg 390 

21 D02007 Ampicillin Cap I.P. 250 mg 455 

22 D02008 Ampicillin Inj. I.P. 500 mg 1556 

23 D21012 Anti Snake Venom Inj. I.P. 10ml (Freeze Dried) 

Polyvalent 

1000 

24 D08013 Artemether Inj 80 mg/ml 1518 

25 D13008 Atenolol Tab 50 mg 911 

26 D13013 Atorvastatin Tab 10 mg 1138 

27 D04023 Atracurium Besilate Inj. 10mg/ml 550 

28 D04007 Atropine Sulphate. Inj. I.P 0.6mg/ml, 1ml amp 987 

29 D06001 Atropine Sulphate Inj. I.P. 0.6mg/ml, 100 ml 911 

30 D02030 Azithromycin Tab 250 mg 805 

31 D02031 Azithromycin Tab 500 mg 805 

32 D26001 Benedicts Reagent 

500ml BOTTLE 380 

33 D14026/ Benzyl Benzoate 

25% w/v, 300 

12 Application I.P 

34 D02009 Benzyl Pencillin I.P. Inj. 10 lakhs units 1677 

35 D15007 Betamethasone IP Eye Drops 0.1%w/v 607 

36 D05004 Betamethasone IP 

Sodium 

Inj. 4mg/ml 911 

37 D14009/ Betamethasone Cream IP 0.1%w/w 607 

12 

Valerate 

38 D20012 Bisacodyl Tab. IP 5mg 607 


39 D04017 Bupivacaine In 

Dextrose 

Inj. 0.50% 1035 

40 D14030/ 

12 

Calamine Lotion 50 ml I.P 300 

41 D22012/ Calcium Carbonate Tab. 625 mg+200 iu 345 

12 With Vitamin D3 

42 D22003 Calcium Gluconate Inj I.P. 10%w/v 683 

43 D07005 Carbamazepine Tab IP 200 mg 531 

44 D11002 Carbidopa 

10mg+Levidopa 

100mg 

Tab IP 10mg/ 100mg 1290 

45 D20013 Carminative Mixture 

(each 10ml,contains:weak 455 

Concentrate. 

ginger tincture bp/IP- 

0.625ml,aromatic spirit of 

ammonia IP- 

0.625ml,peppermint spirit 

bp-0.25ml,chloroform IP- 

0.019ml,sodium 

bicarbonate IP-0.275 gm, 

compound cardamom 

tincture IP-3.0ml,aqua q.s- 

10.00 ml,alcohol 

content:20-26%v/v) 

46 D02035 Cefadroxyl Tab. 500mg 400 

47 D02026 Cefotaxime Sodium 

I.P. 

Inj. 1gm 1518 

48 D02010 Cefotaxime Sodium Inj. I.P. 250mg 1518 

49 D02045 Ceftazidime Inj. 500 mg 600 

50 D02034 Ceftriaxone Inj. 1gm 700 

51 D02019 Cefuroxime Inj. IP 250 mg 1518 

52 D02020 Cefuroxime Inj.IP 750 mg 1518 

53 D02022 Cephalexin Dry Syrup IP 125 mg/5ml 607 

54 D05010 Cetirizine Tab 10 mg 721 

55 D17009 Chlordiazepoxide 

IP 

Tab 10 mg 607 

56 D14022 Chlorhexidine Mouth 

Wash 

0.2%w/v 300 

57 D08009 Chloroquine 

Phosphate I.P. 

Tab 250 mg 607 

58 D05008 Chlorpheniramine 

Maleate IP 

Inj. 10 mg/ml 607 

59 D05006 Chlorpheniramine 

Maleate 

Tab 2 mg 797 

60 D17003 Chlorpromazine I.P. Tab 100mg 592 

61 D17002 Chlorpromazine I.P. Tab 50mg 592 

62 D17035 Cinnarizine Tab 25 mg 450 

63 D15003 Ciprofloxacin Eye 

Ointment 

0.3% W/V 775 

64 D15002 Ciprofloxacin Eye/Ear 

Drops 

0.3%w/v 683 

65 D02012 Ciprofloxacin I.P. Inj. 2 mg/ml 1761 


66 D02011 Ciprofloxacin I.P. Tab 500 mg 987 

67 D07009 Clobazam Tab 5 mg 607 

68 D16009 ClomIPhene Citrate Tab 50mg 850 

69 D17038 Clonazepam Tab. 0.5 mg 650 

70 D17039 Clonazepam Tab. 0.25 mg 650 

71 D13023 Clopidogrel Tab 75 mg 607 

72 D08007/ 

125 

Clotrimazole I.P. Cream 1% w/w 531 

73 D08008 Clotrimazole IP Vaginal Tab 200 mg 531 

74 D02006 Cloxacillin I.P Cap. 250 mg 531 

75 D02029 Cloxacillin I.P Inj 500mg 1035 

76 D17014 Clozapine Tab 25mg 683 

77 D17015 Clozapine Tab 100mg 683 

78 D02001 Co-Trimoxazole IP Tab 160mg+ 800mg 531 

79 D02040 Co-Trimoxazole Tab. 80mg + 400mg 400 

80 D03009/ Cough Syrup Syrup Each 5 ml contains CPM-IP 345 

12 

2mg, Ammonium chloride 

100 mg , sodium citrate 30 

mg, menthol 0.5 mg, Simple 

Syrup base with not less 

than 30% of Sugar-QS. 

81 D05001 Dexamethasone 

Sodium I.P. 

Inj 4 mg/ml 607 

82 D05003 Dexamethasone IP Tab 0.5 mg 607 

83 D12007 Dextran 40 With 

Sodium Chloride 

0.9% IP 

inj. 500 ml Infusion 1973 

84 D18006 Dextrose I.P. Inj 25% 1366 




88 D07007 Diazepam I.P. Inj 5 mg/ml 1032 

89 D17001 Diazepam IP Tab 5mg 812 

90 D01005 Diclofenac Sodium 

IP 


91 D01004 Diclofenac Sodium 

I.P. 

Tab 50 mg. 440 

92 D20009 Dicyclomine HCL IP Inj 10mg/ml 911 

93 D20008 Dicyclomine HCL IP Tab 

10 mg 531 

94 D08003 Diethyl 

Carbamazine IP 

Tab 100 mg 440 

95 D13015 Digoxin IP Inj 0.5mg/2 ml 1518 

96 D13014 Digoxin IP Tab 0.25 mg 1139 

97 D13017 Dobutamine HCL Inj. 50 mg/ml 1518 

98 D20007/ Domperidone IP Tab (Film 

10 mg 493 

12 

Coated) 

99 D13016 Dopamine HCL 

USP 

Inj. 40 mg/ml 1215 

100 D02014/ 

12 

Doxycycline I.P. Tab 100 mg 911 


101 D18007/ Electrolyte P(Multi Inj 500ml 1594 

12 Electrolyte In D 5%) 

102 D13009/ Enalapril Maleate Tab(Film 

2.5 mg 759 

12 

coated) 

103 D13032/ Enalapril Maleate Tab (Film 

5 mg 759 

12 

Coated) 

104 D02015 Erythromycin 

Sterate I.P. 

Tab 250 mg 531 

105 D03009/ Expectorant Mixture Each 5ml contains Tincture 455 

12A 

Concentrat Ipecacuanha IP 66-0.875ml, 

ed Tincture Urgenia IP 66- 

0.75ml, Aromatic Spirit of 

Ammonia IP 66-0.875ml, 

Chloroform IP 0.025ml, 

Water QS 5ml, Alcohol 

Content 23-27% v/v 

106 D03009 Expectorant Mixture Each 5ml contains 455 

Concentrat Camphorated opium 

ed Tincture IP 66-1.62ml, 

Tincture Ipecacuanha IP 66- 

0.875ml Tincture Urgenia IP 

66-0.75ml, Aromatic Spirit 

of Ammonia IP 66-0.875ml 

Chloroform IP 0.025ml, 

Water QS-5ml. Alcohol 

Content 40-45% v/v 

107 D01023 Fentanyl Citrate Inj. 50mg/ml 580 

108 D22006 Ferrous Sulphate Tab 200 mg 380 

109 D08014 Fluconazole Tab. 150 mg 475 

110 D17013 Flufenazine 

Deconate IP 

Inj 25mg/ 1ml 1594 

111 D05016 Flunarizine Tab. 5 mg 300 

112 D12002 Folic Acid IP Tab 5 mg 797 

113 D15012 Framycetin Eye/Ear 

Drops 

0.5% w/v 680 

114 D19002 Frusemide I.P. Inj 10mg/ml 797 

115 D19001 Frusemide I.P. Tab 40mg 417 

116 D14010 Gamabenzenehexa 

Chloride 

Solution 1%w/v 380 

117 D02013 Gentamicin I.P. Inj. 80 mg/2ml 1442 

118 D14017/ 

12 

Gentian Violet BPC Paint 50 ml 380 

119 D21002 Glibenclamide IP Tab 2.5mg 607 

120 D21001 Glibenclamide IP Tab 5mg 607 

121 D21028 Glimepiride Tab. 1 mg 400 

122 D21004 Glipizide IP Tab 5mg 683 

123 D14029/ 

12 

Glycerine I.P. 100gm 300 

124 D14029 Glycerine I.P. 500gm 300 

125 D14007 Glycerine Magsulf 

B.P.C. 

Paste 500 Gram Bottle 380 


126 D14007/ Glycerine Magsulf Paste 50 Gram Bottle 380 

12 

B.P.C. 

127 D04019 Glycopyrrolate Inj. 0.2mg/ml 1215 

128 D17012 Haloperidol IP Inj 5mg/ml 1594 

129 D17010 Haloperidol IP Tab 5 mg 683 

130 D12003 Heparin Sodium IP Inj. 5000 I U/ml 2000 

131 D12004 Heparin-Low 

Molecular Wt. 

Inj. 20mg/0.2ml 6900 

132 D05002 Hydrocortisone 

Sodium Succinate 

IP 

Inj. 100 mg 1366 

133 D01006 Ibuprofen I.P. Tab (Film 

Coated) 

200mg 493 

134 D01016 Ibuprofen I.P. Tab (Film 

Coated) 

400 mg 493 

135 D23001 Iohexol Inj 350mg/ml 1670 

136 D04022 Isoflurane Liquid 100ml 350 

137 D13001 Isosorbide Dinitrate 

I.P. 

Tab 5 mg 759 

138 D13002 Isosorbide 

DinitrateI.P. 

Tab 10 mg 759 

139 D01024 Keterolac Inj. 15 mg 580 

140 D01025 Keterolac . Tab 10 mg 500 

141 D20015 Lactulose Syrup 667mg/ ml 455 

142 D04018 Lignocaine 2% with 

Adrenaline 

Inj. 1:200000 978 

143 D04003 Lignocaine Hcl I.P. Gel 2% 638 

144 D04005 Lignocaine HCL 5% 

(Heavy) I.P. 

Inj. 5% 638 

145 D04004 Lignocaine HCL I.P. Inj. 2% w/v 622 

146 D14024 Liquid Paraffin I.P 100 ml bottle 300 

147 D17034 Lorazepam Inj. 2 mg 1438 

148 D13011 Losartan Potassium Tab. 25 mg 1101 

149 D16007 Magnesium 

Sulphate BP 

Inj. 500mg/ml 455 

150 D18010 Mannitol I.P. Inj. 20%w/v 1366 

151 D01014 Mefenamic Acid Tab 500 mg 607 

152 D21003 Metformin IP Tab 500mg 

607 

153 D05012 Methyl Prednisolone 


I.P. 

154 D05013 Methyl Prednisolone 


I.P. 

155 D16004 Methylergometrin 

Maleate IP 

Inj 500 mg 1518 


Inj. 200mcg/ ml 1063 

156 D20005 Metoclopramide IP Inj. 5mg/ml 911 

157 D20006 Metoclopramide IP Tab. 10mg 531 

158 D13020 Metoprolol IP Tab 25mg 455 

159 D13033 Metoprolol IP Tab 50 mg 455 


160 D02025 Metronidazole IP. Inj 5 mg/ml 1025 

161 D02024 Metronidazole IP Tab 400 mg 319 

162 D02023 Metronidazole IP Tab 200 mg 319 

163 D07011 Midazolam Inj. 1 mg/ml 650 

164 D06007 N-Acetyl Cysteine 

BP 

Inj 200 mg/ml 2277 

165 D06003 Naloxone BP Inj. 400 mcg/ml 1670 

166 D04008 Neostigmine Methyl 

Sulphate I.P. 

Inj 0.5 mg/ml 729 

167 D13034 Nifedipine Retard Tab. 20 mg 500 

168 D13006 Nifedipine Soft Gelatin 

5 mg 531 

Cap 

169 D13005 Nifedipine IP Tab 10 mg 455 

170 D13028 Nitroglycerin Inj 25 mg/5ml 1495 

171 D02016 Norfloxacin I.P. Tab 400 mg 531 

172 D02017 Ofloxacin Tab 200 mg 683 

173 D20014 Ondansetron Inj 2mg/ml 1138 

174 D20011/ ORS Powder I.P Powder Single dose sachet 683 

12 

175 D20018 Pantoprazole Inj. 40mg 650 

176 D20020 Pantoprazole Tab. 20 mg 600 

177 D01009 Paracetamol . Inj 150mg/2ml 607 

178 D01022 Paracetamol Suppository 120mg 300 

179 D01003 Paracetamol IP Syrup 125mg/5ml 683 

180 D01002 Paracetamol I.P. Tab 500 mg. 531 

181 D01008 Pentazocine 

LactateI.P. 

Inj. 30 mg/ml 873 

182 D01007 Pethidine 

Hydrochloride I.P 


183 D05007 Pheniramine 

Maleate 

Tab 25 mg 531 

184 D07003 Phenobarbitone 

Sodium IP 

Inj 200mg/ml 759 

185 D07001 Phenobarbitone I.P. Tab 30 mg 524 

186 D07002 Phenobarbitone I.P. Tab 60 mg 524 

187 D07008 Phenytoin Sodium 

IP 

Inj 50 mg/ml 

987 

188 D07004 Phenytoin Sodium 

IP 

Tab 100 mg 531 

189 D02039 PIPeracilline 4gm + 

Tazobactum 500 Mg 

Inj. 4.5gm 800 

190 D18012 Pottasium Chloride 

I.P. 

Inj 10% w/v 1366 

191 D14011 Povidone Iodine IP 

5% W/V 

Solution 500ml 288 

192 D14008 Povidone Iodine Ointment 5%w/w 266 

193 D25004 Povidone Iodine Scrub 7.50% 205 

194 D16006 Povidone Iodine Vaginal 

Pessaries 

200 mg 288 

195 D06004 Pralidoxime I.P. Inj 1 Gram 987 


196 D05011 Prednisolone IP Tab 10 mg 903 

197 D17041 Prochlorperazine Inj. 12.5mg/ml 550 

198 D17040 Prochlorperazine Tab. 5 mg 550 

199 D05009 Promethazine I.P. Inj. 25 mg/ml 645 

200 D05015 Promethazine Tab. 10 mg 400 

201 D04011 Propofol BP Inj. 1% w/v 1518 

202 D12012 Protamine Sulphate Inj 10 mg/ml 1594 

IP 

203 D14016 Purified Talc Powder 500 Gm 455 

204 D20001 Ranitidine HCL I.P. Inj 50mg /2ml 1139 

205 D20002 Ranitidine HCL I.P. Tab 150mg 653 

206 D18009 Ringer’s Lactate I.P. Inj 500ml 1518 

207 D03006 Salbutamol BP Nebuliser 

Solution 

5mg/ml. 478 

208 D03004 Salbutamol 

Sulphate I.P. 

Tab. 4 mg 683 

209 D03005 Salbutamol IP Syrup 2mg / 5 ml 455 

210 D14025 Salicylic Acid Ointment 10 % w/w, 550 

211 D15011 Saline Nasal 

Drops 

0.65 %w/v 455 

212 D14001/ Silver Sulfadiazine Cream 1% w/w 417 

12A 

IP 

213 D14001/ Silver Sulfadiazine Cream 1% w/w 417 

12 

IP 

214 D14023 Sisomicin Cream 0.1 % w/w 550 

215 D15008 Sodium Bicarbonate 

BP 

Ear Drops 10ml 455 

216 D04012 Sodium Bicarbonate Inj. 7.5% w/v 607 

217 D18002 Sodium Chloride 

0.9% & Dextrose 

5% I.P. 

Inj. NULL 1366 

218 D18001 Sodium Chloride I.P Inj. 0.9%w/v 1366 

219 D18013 Sodium Chloride Irrigation/Dr 

essing 

Solution 

0.9 % w/v 600 

220 D18013/ Sodium Chloride Irrigation/Dr 0.9 % w/v 600 

12 

essing 

Solution 

221 D07010 Sodium Valporate 

IP 

Tab 500mg 531 

222 D07006 Sodium Valproate 

I.P. 

Tab 200 mg 531 

223 D19003 Spironolactone IP Tab 25mg 490 

224 D04013 Succinyl Choline 

Chloride I.P. 

Inj. 50 mg/ml 1139 

225 D25002 Surgical Spirit B.P. Bottle 70% v/v 455 

226 D03007 Terbutaline I.P Inj 0.5 mg/ml 911 

227 D03002 Theophylline and 

Etophylline 

Tab 23 mg+ 77 mg 455 


228 D03001 Theophylline and 

Etophylline 

Inj. 50.6 mg+ 169.4 mg 607 

229 D04014 Thiopentone 

Sodium I.P. 

Inj. 0.5 Gram 1139 

230 D21019/ Thyroxine Sodium Tab 25 mcg 1366 

12 

IP 

231 D21019 Thyroxine Sodium 

IP 

Tab 100 mcg 1366 

232 D15005 Timolol Maleate IP Eye Drops 0.5%w/v 531 

233 D15013 Tobramycin Eye Drops 0.3% v/v 800 

234 D01011 Tramadol Inj. 50mg /ml 1139 

235 D01012 Tramadol Tab 100mg 911 

236 D12015 Tranexamic Acid Inj. 500mg/5ml 580 

237 D12014 Tranexamic Acid Tab. 500 mg 400 

238 D11001 Trihexyphenidyl IP Tab 2mg 607 

239 D15006 Tropicamide IP Eye Drops 1%w/v 689 

240 D14027/ 

12 

Turpentine I.P Liniment 50 ml 300 

241 D02027 Vancomycin 

Hydrochloride 

Inj 500mg 1670 

242 D04020 Vecuronium 

Bromide 

Inj 4mg 1380 

243 D04021 Vecuronium 

Bromide 

Inj 10 mg 1380 

244 D22002/ Vitamin B Complex Tab Each tablet contains 455 

12 NFI (Strong) 

Nictonamide IP 20mg, 

Riboflavin IP 2mg, 

Thiamine HCL IP 5mg 

245 D12001/ Vitamin B12/ Inj 100MCG/ml 863 

12 Cyanocobalamin IP 

246 D12005 Vitamin K1- 

Phytomenadione 

Inj. 10 mg/ml 683 

247 D12016 Vitamin K- 

Menadione 

248 D22004/ 

12 

Vitamin Multy Tab (Film 

coated) 

Inj. 5mg/ml 650 

Each tablet containing 

Vitamin A-2500 iu, Vitamin- 

D 200 iu, Vitamin - D 200 

iu, Vitamin-B1 2mg, 

Vitamin -B2 2mg Vitamin 

B6 0.5mg, Calcium 

Pantothenate-1mg, 

Niacinamide-25mg, 

Vitamin-C 50mg, Folic 

Acid-0.2mg 

249 D18011 Water for Injection 

I.P. 

Inj. 10 ml 1366 

250 D14015/ White Soft Paraffin 

100 gm 380 

12 

IP 

251 D14005 Whitfield Ointment Ointment 15 gm 380 


607

IP 

252 D15009 Xylometazoline I.P. Nasal 

Drops 

0.1% w/v 455 

CATEGORY III 

Sl Drug 

No Code Drug Name 

Blood Administration set with 

Strength RATE 

1 S27009 Microagregate Filter 1 Unit 

16G Cannula/18G Catheter 

1366 

2 S27234 Disposable CVP Catheter 

(45 cm length) 1242 

18G Cannula/20G Catheter 

3 S27235 Disposable CVP Catheter 

(32 cm length) 1242 

4 S27232 Disposable Needle 23G , 1.5 " L 1366 

5 S27030 Disposable Needle 24 G 1366 





10 S27027 Disposable Needle 

Disposable syringe with fixed 

21 G 1366 

11 S27239 Needle 29 G 1ml Graduated 1ml 1961 

12 S27031 Disposable syringe without needle 2 cc 1139 


14 S27218 Disposable syringe without needle 20CC 1139 


16 S27038 I.V. Cannula 24 G 1366 

17 S27034 I.V. Cannula with Injection Port 16 G 1366 




21 S27096 I.V. Set with Needle 1 Unit 1366 

22 S27041 Spinal Needle 23 G 1366 

23 S27238 Spinal Needle 25 G 1366 

24 S27082 Scalp Vein Set 22 G 1 Unit 1366 

25 S27083 Scalp Vein Set 24 G 1 Unit 1366 

26 S27016 BP Blade - 15 Box of 100 1139 




30 S27014 BP Blade – 10 Box of 100 1139 




34 S27039 Disposable Three Way Stopcock 1 Unit 1366 

35 S27045 Endotracheal Tube 2.5 1 Unit 1366 








42 S27054 Endotracheal Tube 5.5 with Cuff 1 Unit 1366 










52 S27222 Epidural Catheter with Cannula 18 G 1242 

53 S27193 Folley's Catheter -14F X 30 ML 1 No 1366 

54 S27067 Folley’s Catheter 10 F X 10 ML 1 Unit 1366 


56 S27063 Folley’s Catheter 16f X 30 ML 1 Unit 1366 



59 S27066 Folley’s Catheter 8 F with stillet 1 Unit 1366 

60 S27070 Infant Feeding Tube 10 F 1 Unit 1366 






66 S27221 Nelaton Catheter Size 12 1242 

67 S27220 Nelaton Catheter Size 14 1242 

68 S27203 Oxygen Cathether 8F 1242 

69 S27205 Oxygen Cathether 12 F 1242 

70 S27204 Oxygen Cathether 10 F 1242 

71 S27076 Ryle’s Tube 10 F 1 Unit 1366 



74 S27079 Ryle’s Tube 16 F 

SICS Blade (Sharp Edge) Cresant 

1 Unit 1366 

75 S27201 

Blade (2.8 mm) 1 NO 1035 

76 S27200 

SICS Blade (Sharp Edge) 

Keratome Blade (2.8 mm) 1 NO 1035 

77 S27202 SICS Blade (Sharp Edge) Side Port 1 NO 1035 

78 S27089 Suction Catheter Size – 10 1 Unit 1366 





83 S27233 Uimbilical Cord Clamp 

Urine Collecting Bag with Valve 

1 Unit 1242 

84 S27095 

85 S27068 

Outlet 2 Ltr 2277 

Vacusuck Set (Moulded 

Transparent having no joints on 

the surface of the tubing) 2.5 m 1366 


Sl. 

No 

1 

CATEGORY IV 

Drug 

Code Drug Name Strength RATE 

S27010 Blood Collection Single Bag 350 ML 1335 

2 

D26006 

Malaria Antigen Detecting Card 

Test 1 Test 3036 

3 S27012 Paediatric Bag 100ML 1518 

4 

Quadruple Bag with SAGM For 5 

S27011 Day Platelet Storage 1No 3036 

5 S27013 TB SAGM 350 ML 1366 

6 D26021 VDRL – RPR Card Test 1 Test 1518 

CATEGORY V 

Sl. Drug 

No Code Drug Name Strength RATE 

1 S27231 Absorbent Cotton Gauze Sch.F(II) 50 cmX7.5m 531 

2 S27007 

S27007/ 

Absorbent Cotton Wool IP 500 gm Net 455 

3 12 Absorbent Cotton Wool IP 200 gm Net 455 

4 S27002 Adhesive Tape U.S.P 10 cm x 5 mtr 911 

Disposable Surgeon’s Cap – 

911 

5 S27099 

Female 1 No 

6 S27098 Disposable Surgeon’s Cap – Male 1 No 911 

Disposable Surgeon’s Mask 

911 

7 S27100 

(Double Layer) 1 No 

Disposable Surgeon’s Mask (Triple 

911 

8 S27195 

Layer) 1 No 

9 S27194 ECG Gel 250 gm 1150 

10 S27086 Gloves Surgical Rubber (ISI) 6.5” 1366 

11 S27088 Gloves Surgical Rubber (ISI) 7.5” 1366 

12 S27085 Gloves Surgical Rubber (ISI) 6” 1366 

13 S27087 Gloves Surgical Rubber (ISI) 7” 1366 

Gloves Surgical Rubber -Sterile 

1366 

14 S27199 

(ISI) 7.5 


1366 

15 S27196 

(ISI) 6 


1366 

16 S27198 

(ISI) 7 


1366 

17 S27197 

(ISI) 

Haemostatic Gelatine Sponge with 

uniform porosity in Hollow 

Cylindrical Shape for Rectal 

6.5 

18 S27173 

Procedures 1 No 1139 


19 S27004 Hypo Allergic Acrylic Paper Tape 5 cm x 9 .1 mtr 903 

20 S27003 Hypo Allergic Acrylic Paper Tape 2.5cm x 9.1 mtr 903 

21 S27005 Hypo Allergic Acrylic Paper Tape 

Non Adherent Sterile Rayon 

Dressing Impregnated With 10% 

7.5cm x 9.1 mtr 903 

22 S27172 

Povidone Iodine 10x10 cm 1139 

23 S27230 Plaster of Paris Bandage B.P 10 cm x 2.7 m, 607.2 

24 S27001 Plaster of Paris Bandages B.P 

Polyurethane Nasogastric Feeding 

15cm x 2.7mtr 607.2 

25 S27101 

Tube 15(CH/FR) 100 cm 1518 

26 S27075 Rubber Sheet Mackintosh 1 mtr 1366 

CATEGORY VI 

Sl. Drug 


Black Disinfectant Fluid 

Strength RATE 

1 D25012 (Gr-III RWC 5.7) BIS 5 Ltr 531 

2 D25011 Bleaching Powder 

ChlorhexidineGluconate + Ethyl 

30% 304 

3 D25010 Alcohol 2.5% +70% v/v 759 

4 D25005 Chloroxylenol Solution 5% 531 

5 D25006 Chloroxylenol Solution 5% 531 

6 D25014 Formaldehyde Solution Ip 37% w/v 380 

7 D25007 

D25003/ 

Gluteraldehyde without Surfactant 5 Ltr 455 

8 12 Hydrogen Peroxide Solution I.P. 

Nonoxylenol Surfactant based 

20 Vol 288 

9 D25009 Iodine Solution 10% 531 

10 D25008 Orthothaladehyde 0.50% 455 

11 D25013 Washing Soda 1 Kg 455 

CATEGORY VII 

Sl. Drug 


Black Silk 5-0 1/2 Circle, Taper 

Cut /Cutting Needle 17mm, 70- 

Strength RATE 

1 S27505 90 cm NULL 1139 

Braided Polyglycolic Acid Suture- 

1, 70-90cm, 1/2 Circle Taper Cut 

1139 

2 S27506 (Heavy)40mm Needle NULL 

Braided Polyglycolic Acid Suture 

1-0, 70- 90cm, 1/2 Circle Taper 

1139 

3 S27507 Cut 40mm Needle NULL 


1139 

S27508/ 3-0, 40- 50cm, 3/8 Circle Cutting 

4 12 12mm Needle NULL 


5-0, 45cm, 3/8 Circle Reverse 

1139 

5 S27509 Cutting 12mm Needle NULL 


6 S27510 

7 S27511 

8 S27512 

9 S27513 

10 S27514 

11 S27515 

12 S27516 

13 S27517 

14 S27518 

15 S27519 

16 

S27520/ 

12 

17 S27521 

18 

19 

20 

S27522/ 

12 

S27523/ 

12 

S27524/ 

12 

21 S27525 

22 S27526 

23 S27527 

24 S27529 


6-0, 45cm, 3/8 Circle Reverse 

Cutting 12mm Needle NULL 

Catgut Chromic 2-0,70- 90 cm, 

1/2 CRB 30mm Needle NULL 

Catgut Chromic 3-0,76 cm, 1/2 

Circle Reverse Cut ,12mm Needle NULL 

Catgut Chromic 3-0,70-90 cm, 1/2 

CRB, 20mm Needle NULL 

Catgut 4-0, 1/2 Circle , Round 

Body Needle 16mm,70-90 cm NULL 

Catgut 6-0, 3/8 Circle,Cutting 

Needle, 8mm, 40-50 cm NULL 

Catgut No.1 RB 34-40 mm 

Needle,70-90 cm NULL 

Catgut No.1/0 RB 34-40 mm 

Needle, 70-90 cm NULL 

Monofilament Polyamide 10/0 , 

3/8 Circle Micropoint Round Body 

Needle 4mm,20-30 cm NULL 

Monofilament Polyamide 10/0, 1/2 

Circle Double Needle 6mm,30-40 

cm NULL 

Monofilament Polyamide 2-0, 30- 

36mm, 3/8 Circle Cutting Needle, 

70-90cm NULL 


36mm, 3/8 Circle Cutting Needle, 

40-50 cm NULL 


36mm, 3/8 Circle Cutting Needle 

,40-50 cm 

NULL 


36mm,3/8 Circle Cutting 

Needle,70-90cm NULL 

Monofilament Polyamide 8/0, 3/8 

Circle Reverse Cutting Micro point 

8mm, 30-40cm NULL 

Monofilament Polypropylene Blue 

1, 70-90cm 1/2 Crb (Heavy) 

40mm NULL 


1-0, 70-90cm 1/2 CRB 30mm NULL 


3-0, 70-90cm, 3/8 Circle Cutting 

22mm NULL 

Poliglecaprone 25, Undyed, Size 

3/0 with 3/8 Circle Cutting / 

Reverse Cutting Needle 24- 

28mm,70-90 cm NULL 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 


25 S27572 

26 S27531 

27 S27574 

28 S27532 

29 S27533 

30 S27534 

31 S27535 

32 S27536 

33 S27537 

34 S27538 

35 S27539 

36 S27540 

37 S27541 

38 S27542 

39 S27543 

40 

S27544/ 

12 

41 S27545 

42 S27546 

43 S27547 

Glyconate, Undyed, Size 3/0 With 

3/8 Circle Cutting / Reverse Cutting 

Needle 24-28mm,70-90 Cm NULL 

Poliglecaprone 25, Undyed, Size 

5/0 With 3/8 Circle Cutting / 

Reverse Cutting Needle 12-15 

Mm,70-90 Cm NULL 

Glyconate, Undyed, Size 5/0 with 

3/8 Circle Cutting / Reverse Cutting 

Needle 12-15 Mm,70-90 cm NULL 

Polydiaxone 6-0, Cutting Needle, 

3/8 Circle,13mm,40-50 cm NULL 

Polydioxanone Of Size 1 with ½ 

Circle RB, 45- 50mm Heavy 

Needle Suture Length 1.5 M, for 

Sheath Closure NULL 

Polyglactin 910 4-0, Undyed, 

Cutting Needle 3/8 Circle , 16- 

20mm,70-90 Cm NULL 

Polyglactin 910 4-0,Round Body 

Needle 3/8 Circle , 20mm,70-90 

Cm NULL 

Polyglactin 910 of Size 1,1/2 Circle 

Round Body Needle,35-40 Mm 

,70-90 Cm NULL 

Polyglactin 910 of Size 1-0,1/2 

Circle Round Body 30- 36mm,70- 

90 Cm NULL 

Polyglactin 910, Size 2-0,1/2 CRB, 

30mm Needle ,70-90cm NULL 

Polyglactin 910,Size 3-0,1/2 CRB, 

26-30mm Needle ,70-90cm 

NULL 

Polyglycolic Acid 2-0, 1/2 CRB, 30 

mm,70- 90 cm NULL 

Polyglycolic Acid 3-0, 1/2 CRB, 

20 mm, 70-90 cm NULL 

Polyglycolic Acid 3-0, 1/2 CRB, 

30 mm, 70-90 cm NULL 

Polyglycolic Acid No. 1, 1/2 CRB 

40mm, 70-90 cm NULL 

Polyglycolic Acid Size 1-0 with 

Cutting1/2 Circle Needle 36mm, 

70-90 cm NULL 

Polyglycolic Acid Size 1 with 

Reverse Cutting 1/2 Circle Needle 

40mm,70-90 cm NULL 

Polyglycolic Acid Size 5/0 with 1/2 

Circle Cutting Needle 12mm,70-90 

cm NULL 

Polyglycolic Acid Size 6/0 with 

Micropoint Spatulate 8mm,Double NULL 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 


44 S27549 

45 S27550 

46 S27553 

47 S27555 

48 S27556 

49 S27557 

50 

S27559/ 

12 

51 S27560 

S27561/ 

52 12 

53 S27562 

54 S27563 

55 S27564 

56 S27565 

57 S27566 

58 S27567 

59 S27568 

S27569/ 

60 12 

61 S27570 

Needle, 70-90 cm 

Polypropylene 2-0, 1/2 CRB 26- 

30mm Needle ,70-90 cm NULL 

Polypropylene 3-0, 1/2 CRB 24- 

26mm Needle, 70-90 Cm NULL 

Polypropylene 5-0, 3/8 Round 

Body 12mm Needle ,70-90 cm NULL 

Polypropylene 6-0, 3/8 Circle 

Taper Cut, Double Arm 

Needle,13mm,70-90 cm NULL 

Polypropylene 7-0, 3/8 Circle, 

Taper Cut 8mm Double Armed 


Polypropylene Mesh 0.02 

Thickness With 1.9kg Burst 

Strength Per Square Cm Hernia 

Repair(15x15 Cm) NULL 

Polypropylene Mesh 0.02 

Thickness With 1.9kg Burst 

Strength Per Square cm Hernia 

Repair(7x15 cm) NULL 

Polypropylene, 6-0,3/8 Circle 

Reverese Cutting, 12mm 


Surgical Silk 2-0, 1/2 Circle cutting 

Needle 30mm,70-90 cm NULL 

Surgical Silk 3-0, 1/2 Circle Cutting 

Needle 30mm ,70-90 cm NULL 

Surgical Silk 3-0, 1/2 CRB 20mm 


Surgical Silk 4-0, 1/2 Circle Taper 

cut Needle 17mm,70-90 cm NULL 

Suture Pack Silk No. 1, 2x70-90 

cm NULL 

Suture Pack Silk No. 1-0, 2x70-90 

cm NULL 

Suture Pack Silk No. 2, 2x70-90 

cm NULL 


cm NULL 


cm NULL 

Virgin Silk 8/0, 3/8 Circle Micro 

Point Spatulated Double Arm 

Needle 6mm, 30-40 cm NULL 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 

1139 


DETAILS OF LABRATES FOR THE DRUGS ADDITIONALLY INCLUDED 

CATEGORY I 

Sl. Drug 

Dosage 


Form Stength Rates Remarks 

1 D19006 Acetazolamide Tab I.P Tab 250mg 300 

2 D13036 Acetyl salicylic acid Tab I.P Tab 

3 

150mg 

(enteric 

coated) 380 

D06002/ 

12 Activated charcoal powder Powder 10gm 304 

4 D15014 Acyclovir eye ointment Ointment 3% 300 

5 D09004 Acyclovir syrup Syrup 

400mg/5 

ml 350 

6 D09005 Acyclovir tab I.P Tab 800mg 683 

7 D13037 Adenosine inj Inj 3mg/ml 650 

8 D12018 Albumin IV 20% 1138 

9 D29001 Alendronate Tab Tab 35mg 350 

10 D13038 Alpha Methyl Dopa Tab Tab 500mg 350 

11 D13039 Alpha Methyl Dopa Tab Tab 250mg 350 

12 D17053 Alprazolam Tab Tab 0.5mg 531 

13 D03010 Ambroxol Syrup SYRUP 30mg/5ml 350 

14 D15015 Amikacin Eye Drops 

EYE 

DROPS 1% 350 

15 D13040 Amiodarone Inj INJ 50mg/ml 350 

16 D13041 Amiodarone Tab I.P Tab 100mg 350 

17 D02047 

18 D02048 

Amoxycillin + Clavulanic acid 

Dry Syrup 

Amoxycillin + Clavulanic acid 

Dry Syrup 

DRY 

SYRUP 

DRY 

SYRUP 

200mg + 

28mg 350 

400mg+56 

mg 350 

19 D02049 Amoxycillin + Clavulanic Inj INJ 1.2 g/10 ml 350 

20 D02033 Amoxycillin dry Syrup 

DRY 

SYRUP 250mg/5ml 805 


21 D08018 Amphotericin Inj Liposomal I.P 

INJ 

LIPOSOM 

AL I.P 50mg 350 

22 D02050 Ampicillin Syrup I.P SYRUP I.P 250mg/5ml 350 

23 D02051 Ampicillin Syrup I.P SYRUP I.P 125mg/5ml 350 

24 D08019 Artesunate Inj INJ 60mg 350 

25 D08020 Artesunate Tab Tab 50mg 350 

26 D13042 Atenolol Tab Tab 25mg 911 

27 D17044 Atomoxetine Tab Tab 10mg 350 

28 D17045 Atomoxetine Tab Tab 25mg 350 

29 D13043 Atorvastatin Tab Tab 20mg 1138 

30 D15016 Atropine Eye Drops 

EYE 

DROPS 1% 350 

31 D15017 Atropine Eye Ointment I.P 

EYE 

OINTMEN 

T I.P 1% 350 

32 D02052 Azithromycin Inj INJ 500mg 350 

33 D02053 Azithromycin Syrup SYRUP 

100mg/5 

ml 350 

34 D02054 Azithromycin Tab Tab 2 gm 805 

35 D01026 Baclofen Tab Tab 5mg 350 

Balanced salt Solution (glass SOLUTIO 

36 D15018 bottle for ophthalmic use) N 500 ml 300 

37 D05017 Betahistine Tab Tab 8mg 350 

38 D15019 Bimatoprost Eye Drops 

EYE 

DROPS 0.03% 350 

39 D20025 Bisacodyl Tab Tab 10mg 607 

40 D15020 

Boric acid 1 % with Naphazoline 

0.056 % +Phenyl ephrine 0.12 

% Eye drops Eye Drops 

1% + 

0.056% + 

0.12% 350 

41 D15021 Brimonidine eye drops Eye Drops 0.20% 350 

42 D11005 Bromocriptine tab Tab 1.25mg 350 

43 D03011 Budesonide nasal spray 

Nasal 

Spray 

50 

mcg/puff 350 

44 D17046 Buspirone tab Tab 5mg 350 


45 D11006 Cabergoline tab Tab 0.5mg 350 

46 D22013 Calcitriol + calcium tab Tab 

25 mcg + 

500mg 350 

47 D22017 Calcium carbonate tab Tab 500mg 300 

48 D07012 Carbamazepine ER Tab I.P Tab 400mg 531 

49 D07013 Carbamazepine syrup Syrup 

200mg/5 

ml 350 

50 D21033 Carbimazole tab Tab 10mg 350 

51 D15022 

Carboxymethyl celluylose sodium 

ophthalmic solution 

[PRESERVATIVE FREE] 

OpthalmicS 

olution 0.50% 300 

52 D13044 Carvedilol tab Tab 3.125mg 350 

53 D13045 Carvedilol tab Tab 6.25mg 350 

54 D02055 Cefixime tab i.p Tab 200mg 350 

55 D02056 Cefoperazone + sulbactam inj Inj 

1gm+ 

0.5gm 350 

56 D02057 Cefpodoxime proxetil tab Tab 200mg 350 

57 D02058 Cefuroxime inj Inj 1.5gm 1518 

58 D02059 Cefuroxime tab Tab 500mg 350 

59 D05018 Cetirizine syrup I.P Syrup 5mg/ ml 350 

60 D05019 Chlopheniramine maleate tab I.P Tab 4mg 797 

61 D02060 Chloramphenicol cap I.P Cap 250mg 350 

62 D02061 Chloramphenicol syrup I.P Syrup 125mg/5ml 350 

63 D17047 Chlordiazepoxide TAB Tab 25mg 607 

64 D15023 

Chlorophenamine maleate + 

Phenyl ephrine + Naphazoline 

Eye drops Eye Drops 

0.01 % + 5 

% + 0.056 

% 350 


65 D15024 

Ciprofloxacin + Dexamethasone 

Ear drops Ear Drops 

0.3 %+ 0.1 

% 350 

66 D02063 Ciprofloxacin + tinidazole tab Tab 

500mg + 

600mg 350 

67 D02062 Ciprofloxacin tab Tab 250mg 987 

68 D02064 Clarithromycin syrup Syrup 125mg/5ml 350 

69 D02065 Clarithromycin tab i.p Tab 500mg 350 

70 D02066 Clindamycin inj Inj 

300mg/ 

2ml 350 

71 D02067 Clindamycin vaginal tab Tab 200mg 350 

72 D14031 Clobetasol propionate cream 0.05% 350 

73 D16010 Clomiphene citrate tab Tab 100mg 850 

74 D13046 Clonidine tab i.p Tab 100mcg 350 

75 D08021 Clotrimazole Mouth paint 

Mouth 

Paint 1% 300 

76 D02068 Cloxacillin cap i.p Cap 500mg 531 

77 D02069 Cloxacillin DT Tab 250mg 350 

78 D02070 Cloxacillin syrup I.P Syrup 125mg/5ml 350 

79 D02071 Cotrimoxazole TAB Tab 100/ 20mg 400 

80 D15025 

Cyclopentolate 1 % and Phenyl 

ephrine 5 % ophthalmic solution 

OpthalmicS 

olution 1 % + 5 % 350 

81 D05020 Deflazacort Tab Tab 1mg 350 

82 D05021 Deflazacort Tab Tab 6mg 350 

83 D15026 Dexamethasone Eye drops Eye Drops 0.01% w/v 350 

84 D04024 Dexmeditomedine Inj Inj 200 mcg 300 

85 D17049 Diazepam Tab Tab 10mg 812 

86 D17048 Diazepam Tab Tab 2mg 812 

87 D01027 Diclofenac potassium Tab Tab 50mg 285 


88 D01028 Diclofenac sodium Gel Gel 1% w/w 350 

89 D20026 Dicyclomine Tab Tab 20mg 531 

90 D08022 Diethyl carbamazine Syrup Syrup 50mg/5ml 350 

91 D22014 Disodium hydrogen citrate Syrup Syrup 1.4gm/5ml 250 

92 D15027 

Dorzolamide + Timolol Eye 

drops Eye Drops 

2 % + 0.5 

% 350 

93 D15028 Dorzolamide eye drops Eye Drops 2% 300 

94 D03012 Doxophylline tab Tab 400mg 300 

95 D02072 Doxycycline DT I.P Tab 100mg 350 

96 D20027 Doxylamine TAB Tab 10mg 300 

97 D16011 Dydrogesterone TAB I.P Tab 10mg 300 

98 D29002 Ephedrine Inj Inj 30mg/ml 300 

99 D02073 Erythromycin Tab Tab 500mg 531 

100 D01030 Etodolac Tab Tab 400mg 300 

Ferrous ascorbate equivalent to 

100mg + 

101 D22015 elemental iron + Folic acid Tab Tab 

1.5mg 350 

102 D05022 Fexofenadine Tab I.P Tab 120mg 350 

103 D08023 Fluconazole INJ Inj 

200mg/100 

ml 350 

104 

D05016/ 

12 Flunarizine TAB Tab 5mg 300 

105 D05037 Flunarizine TAB Tab 10mg 300 

106 D23004 Fluorescein INJ Inj 20% 350 

107 D15029 

108 

Fluoromethosone ophthalmic 

solution 

OpthalmicS 

olution 0.10% 350 

D17008/ 

12 Fluoxetine Cap Cap 10mg 759 

109 D17050 Flupenthixol decanoate Inj Inj 20mg/ml 350 

110 D15030 Flurbiprofen eye drops Eye Drops 0.03% 350 

111 D07015 Fosphenytoin inj Inj 

750mg/10 

ml 350 

112 D14012 Framycetin skin cream 1% W/W Skin Cream 20 gm 350 


113 D14032 Fusidic acid Ointment Ointment 2% 350 

114 D07016 Gabapentin Tab Tab 100mg 350 

115 D09006 Ganciclovir Ophthalmic Gel 0.15% 350 

116 D15031 Gatifloxacin eye drops Eye Drops 0.30% 350 

117 D15032 Gentamicin Ear/Eye drops I.P 

118 D14033 

Gentamicin + clotrimazole + 

beclomethasone cream 

Eye / Ear 

Drops 0.30% 350 

0.1% + 

1% + 

0.025% 350 

Gentamicin + Dexamethasone 

0.3%+ 

119 D15033 Ear Drops Ear Drops 0.1% 350 

120 D17051 Ginkgo biloba TAB Tab 40mg 350 

121 

D21032/ 

12 Glimepiride TAB Tab 2mg 400 

122 D13047 Glyceryl trinitrate TAB Tab 2.6mg 350 

123 D17052 Haloperidol TAB Tab 1.5mg 683 

124 D16012 

High dose desogestrel + Ethinyl 

estradiol TAB Tab 

0.15mg+ 

0.03mg 350 

125 D15034 Homatropine Eye drops Eye Drops 2% 350 


126 D02074 Hpylori kit 

Each 

combi pack 

contains, 

(Amoxycilli 

n 750mg-2 

Tab) + 

(Omeprazol 

e 20mg- 2 

Cap) + 

(Tinidazole 

500mg- 2 

Tab) 350 

127 D04025 Hyaluronidase INJ Inj 1500 IU 300 

128 D13048 Hydralazine injection Inj 20mg/ml 300 

129 D08024 Hydroxy chloroquine tab Tab 200mg 350 

130 D16013 

131 D15035 

132 D15036 

133 D15037 

Hydroxy progesterone caproate 

inj i.p Inj 250mg/ ml 350 

Hydroxy propyl methyl cellulose 

0.3 % with preservative eye 

drops Eye Drops 0.30% 350 

Hydroxypropyl methyl cellulose 

ophthalmic solution 2% 350 

Hydroxypropyl methyl cellulose 

ophthalmic solution 2% 350 

134 D05023 Hydroxyzine syrup Syrup 10mg/5ml 350 

135 D05024 Hydroxyzine tab Tab 25mg 350 

136 D05025 Hydroxyzine tab Tab 10mg 350 

137 D20028 Hyoscine butyl bromide inj i.p Inj 20mg/ml 350 

138 D20029 Hyoscine butyl bromide tab Tab 10mg 350 


139 D29003 Ibandronate tab Tab 150mg 350 

140 D01031 Indomethacin cap I.P Cap 25mg 350 

141 D03013 Ipratropium nebulising solution 250mcg 350 

142 D22016 Iron sucrose intravenous INJ Inj 

100mg 

elemental 

Iron/5ml 350 

143 D13049 Isosorbide mononitrate tab Tab 20mg 759 

144 D08025 Ivermectin tab Tab 3mg 300 

145 D08026 Ivermectin tab Tab 6mg 300 

146 D04001 Ketamine inj i.p. Inj 50 mg/ml 751 

147 D08030 Ketoconazole cream 2% 300 

148 D15038 

ketorolac tromethamine Eye 

drops Eye Drops 0.50% 300 

149 D13050 Labetalol Inj Inj 20mg/4ml 350 

150 D13051 Labetalol Tab Tab 100mg 350 

151 D13052 Labetalol Tab Tab 200mg 350 

152 D20030 Lactulose Syrup Syrup 10g/15ml 455 

153 D07017 Levetiracetam Syrup Syrup 100mg/ml 300 

154 D07018 Levetiracetam Tab Tab 500mg 300 

155 D03014 Levo salbutamol Respules 

0.63mg/2.5 

ml 300 

156 D03015 Levo salbutamol TAB Tab 2mg 350 

157 D05026 Levocetirizine Syrup Syrup 2.5mg/5ml 350 

158 D05027 Levocetirizine Tab I.P Tab 5mg 350 

159 D11007 Levodopa+Carbidopa TAB Tab 

160 D15039 

Levofloxacin + Dexamethasone 

EAR DROPS Ear Drops 

25mg+ 

100mg 1290 

0.3 %+ 0.1 

% 350 

161 D15040 Levofloxacin Ear drops 

EYE 

DROPS 0.30% 350 

162 D02075 Levofloxacin Tab i.p Tab 500mg 350 


163 D04026 Lignocaine topical Spray 10% 350 

164 D02076 Linezolid Inj Inj 

165 D02077 Linezolid Inj Inj 

200mg/100 

ml 350 

200mg/100 

ml 350 

166 D02079 Linezolid Syrup Syrup 100mg/5ml 350 

167 D02078 Linezolid Tab I.P 600mg 350 

168 D17060 Lorazepam INJ Inj 2mg/ml 1438 

169 D13053 Losartan TAB I.P Tab 50mg 1101 

170 D16014 

171 D12019 

Low dose desogestrel + Ethinyl 

estradiol Tab Tab 

Low molecular weight heparin 

INJ Inj 

0.15mg+ 

0.02mg 350 

40mg/0.4 

ml 6900 

172 D21036 L-thyroxine Tab Tab 50 mcg 1366 



175 D29004 Lugol's iodine I.P 

(for oral 

use) 350 

176 D16023 Magnesium sulfate INJ Inj 20 %w/v 455 

177 D16016 

Medroxy progesterone acetate 

Tab Tab 10mg 350 

178 D16015 Medroxy progesterone depot INJ Inj 

150mg/30 

ml 350 

179 D01032 Mefenamic acid DT Tab 250mg 350 

180 

D24008/ 

12 Methotrexate Tab I.P Tab 2.5mg 450 

181 D17054 Methyl phenidate Tab Tab 10mg 350 

182 D05028 Methyl prednisolone INJ Inj 1 gm 1518 

183 D02086 Metronidazole Gel 1% 350 

184 D14034 Miconazole Cream I.P 2% 350 

185 D16017 Mifepristone Tab Tab 200mg 350 

186 D03016 Mometazone Nasal spray 

50 

mcg/puff 350 

187 D05029 Monteleukast Tab Tab 10mg 350 

188 D05030 Monteleukast Tab Tab 5mg 350 


189 D01010 Morphine sulphate Inj. I.P. Inj 15 mg/ml 350 

190 D15041 Moxifloxacin Eye drops Eye Drops 0.50% 350 

191 D14035 Mupirocin Ointment Ointment 2% 350 

192 D06014 N-Acetyl Cysteine Inj Inj 1g 2277 

193 D06015 N-Acetyl cysteine TAB Tab 600mg 350 

194 D06016 Naloxone inj I.P Inj 

200 

mcg/ml 300 

195 D01033 Naproxen tab I.P Tab 500mg 300 

196 D15042 Natamycin Eye drops Eye Drops 5% 300 

197 D16018 Natural micronised progesterone S.G. Cap 100mg 300 

198 D16019 Natural Micronised Progesterone S.G. Cap 200mg 300 

199 D15062 

200 D15063 

201 D15043 

Neomycin + Polymyxin 

Ointment Ointment 

Neomycin +Polymyxin 

+Hydrocortisone Ointment Ointment 

Neomycin 3400u +Polymyxin 

10000u +Hydrocortisone 10mg 

/Ml Ear Drops Ear Drops 

(1700U + 

5000U) / 

gm 350 

(3400U + 

10000U + 

10mg) /gm 350 

(3400U + 

10000U 

+100 mg) / 

ml 350 

202 D15044 Nepafenac Eye Drops Eye Drops 0.10% 300 

203 D02080 Nitrofurantoin I.P Tab Tab 100mg 300 

204 D29005 Noradrenaline Bitartrate Inj I.P Inj 4mg/2ml 300 

205 D16020 Norethisterone Tab I.P Tab 5mg 300 

206 D15045 

Octofluoropropane 

(C3f8)Ophtalmic Prepn 

OpthalmicP 

reparation 30ml 300 


207 D24052 Octreotide Inj Inj 50 mcg/ml 350 

208 D02081 Ofloxacin + Ornidazole Tab Tab 

200mg + 

500mg 300 

209 D15046 Ofloxacin Ear / Eye Drops 

Eye / Ear 

Drops 0.30% 350 

210 D02018 Ofloxacin Inj. Inj 2 mg/ml 1670 

211 D13054 Olmesartan Tab Tab 20mg 350 

212 

D20004/ 

12 Omeprazole Cap Cap 20mg 1366 

213 D20031 Ondansetron Inj I.P Inj 4mg/ml 1138 

214 D20032 Ondansetron Tab I.P Tab 4mg 350 

215 D09007 Oseltamivir Cap I.P Cap 75mg 350 

216 D07019 Oxcarbazepine Tab Tab 150mg 350 

217 D15047 Oxymetazoline Nasal Drops 

Nasal 

Drops 0.05% 350 

218 D16021 Oxytocin Inj Inj 10 IU 1898 

219 D16001 Oxytocin Inj. I.P. Inj 5 IU/ml 1898 

220 D20033 Pantoprazole Tab Tab 40mg 600 

221 D20034 

Pantoprazole+ Domperidone 

Cap Cap 

40mg 

+10mg 350 

222 D01034 Paracetamol Syrup/Susp I.P Syrup 250mg/5ml 683 

223 D01035 Paracetamol Infusion Infusion 1gm/100ml 607 

224 D02082 Penicillin V Tab Tab 250mg 350 

225 D15048 

Perflouro-N-Octane Liquid Sterile 

Ophthalmic Prepn 

OpthalmicP 

reparation 5 ml 350 

226 D14036 Permethrin Cream Cream 5% 350 

227 D14037 Permethrin Lotion Lotion 5% 350 

228 D01039 Pethidine Inj I.P Inj 50mg/ml 350 

229 D05031 Pheniramine Syrup Syrup 

22.75mg/m 

l 350 

230 D29006 Phenylephrine Inj Inj 10mg/ml 350 

231 D07020 Phenytoin Syrup Syrup 30mg/5 ml 350 

232 D15049 Pilocarpine Nitrate Eye Drops Eye Drops 2% 350 

233 D15064 Pilocarpine Nitrate Inj Inj 0.50% 


234 D02039 Piperacillin + Tazobactam Inj Inj 

235 D02083 Piperacillin+ Tazobactam Inj Inj 

4gm + 

500mg 350 

2gm + 

250mg 350 

236 D02084 Piperacillin+ Tazobactam Inj Inj 

1gm + 

125mg 350 

237 D01040 Piroxicam Tab I.P Tab 10mg 350 

238 D15050 

Polyvinyl Alchohol 1.4 % + 

Povidone Iodine 0.6 % With 

Preservative Drops Drops 

1.4 % + 

0.6% 350 

239 D18014 Potassium Chloride Inj Inj 15% 350 

240 D18015 Potassium Citrate Solution Solution 

Potassium 

Citrate- 

1100 mg + 

Citric Acid- 

334 mg 350 

241 D15051 Povidone Iodine Solution I.P Solution 5% 288 

242 D13055 Prazosine Tab Tab 2.5mg 350 

243 D13056 Prazosine Tab Tab 5mg 350 

244 D15052 

Prednisolone Acetate Eye/Ear 

Drops 

Eye / Ear 

Drops 1% 350 

245 D05032 Prednisolone Tab I.P Tab 40mg 903 



248 D04027 Prilocaine Lignocaine Cream 

249 D15053 

Proparacaine Hcl Ophthalmic 

Solution Usp 

2.5% + 

2.5% 350 

Opthalmic 

Solution 0.50% 350 

250 D04010 Propofol Inj Inj 1% W/V 1518 

251 D13057 Propranolol La Tab Tab 40mg 546 

252 

D13029/ 

12 Propranolol Tab Tab 20mg 546 

253 D13058 Propranolol Tab I.P Tab 10mg 546 

254 D21037 Propyl Thio Uracil Tab I.P Tab 50mg 350 


255 D08028 Pyrantel Palmoate Syrup Syrup 

250mg/5 

ml 350 

256 D08027 Pyrantel Palmoate Tab Tab 250mg 350 

257 D17055 Quetiapine Tab Tab 200mg 600 

258 D17056 Quetiapine Tab Tab 100mg 600 

259 D08010 Quinine Inj Inj 300 mg/ml 850 

260 D08029 Quinine Tab Tab 600mg 350 

261 D13059 Ramipril Tab Tab .5mg 350 

262 D20035 Ranitidine Inj Inj 25mg/ml 1139 

263 D29007 Risedronate Tab Tab 35mg 350 

264 D17057 Risperidone Tab Tab 4mg 531 

265 D03017 Salbutamol Mdi 

100 

mcg/puff 350 

266 D14038 Salicylic Acid Ointment Ointment 12% 550 

267 D14039 Salicylic Acid Ointment Ointment 3% 550 

268 D18016 Saline Inj Inj 3% 350 

269 D03018 Salmeterol + Fluticasone Mdi 

25 mcg+ 

125 mcg 350 

270 D03019 Salmeterol + Fluticasone Mdi 

50 mcg + 

250mcg 350 

271 D11008 Selegilline Tab Tab 5mg 350 

272 D01041 Serratiopeptidase Tab I.P Tab 10mg 350 

273 D04028 Sevoflurane Liquid 300 

274 D15054 Silicon Oil Inj Inj 1000CST 300 

275 D14001 Silver Sulfadiazine Cream Ip Cream 1% w/w 417 

276 D15055 

277 D15056 

Sodium Chloride Ophthalmic 

Ointment 

Sodium Chloride Ophthalmic 

Solution 

Opthalmic 

Ointment 6% 300 

Opthalmic 

Solution 5% 300 

278 D07021 Sodium Valproate Inj Inj 100mg/ml 300 


279 D07022 Sodium Valproate Inj Inj 200mg/ml 300 

280 D07023 

Sodium Valproate Oral Solution 

I.P 

Oral 

Solution 200mg/5ml 300 

281 

D19004/ 

12 Spironolactone Tab Tab 100mg 490 

282 D20036 Sucralfate Syrup Syrup 1g/5ml 300 

283 

D01015/ 

12 Sulfasalazine Tab Tab 500mg 911 

284 D01042 Tapentadol Tab Tab 50mg 300 

285 D13060 Telmisartan Tab I.P Tab 20mg 300 

286 D13061 Telmisartan Tab I.P Tab 40mg 300 

287 D03020 Terbutaline Inj Inj 0.25 mg/ml 911 

288 D03021 

Theophylline & Etophylline Sr 

Tab Tab 150mg 300 

289 D01043 Thiocholchicoside Cap I.P Cap 4mg 300 

290 D02085 Tinidazole Tab I.P Tab 500mg 300 

291 D15057 

Tobramycin + Dexamethasone 

Ear Drops Ear Drops 

0.3% + 

0.1% 300 

292 D15058 Tobramycin Ear Drops Ear Drops 0.30% 800 

293 D15059 Tobramycin Eye Ointment 

Eye 

Ointment 0.30% 300 

294 D01044 Tolperisone Tab Tab 150mg 300 

295 D01045 Tramadol Preservative Free Inj Inj 100mg/2ml 1139 

296 D05035 Triamcinolone Acetonide Inj I.P Inj 40mg/ml 300 

297 D05036 

Triamcinolone Acetonide 

Preservative Free Inj Inj 40mg/4ml 300 

298 D17058 Triclofos Sodium Syrup Syrup 500mg/5ml 300 

Tropicamide + Phenylephrine Opthalmic 1% + 

299 D15060 Ophthalmic Solution 

Solution 2.5% 300 

300 D23005 Trypan Blue Inj Inj 0.06% 300 

301 D22018 Trypsin, Chymotrypsin Tab Tab 100000 U 300 


302 D20037 Ursodeoxycholic Acid Tab Tab 300mg 300 

303 

304 

305 

D17031/ 

12 Venlafaxine Tab Tab 37.5mg 300 

D17032/ 

12 Venlafaxine Tab Tab 75mg 300 

D13007/ 

12 Verapamil Tab I.P Tab 40mg 531 

306 D22019 Vitamin B1+ B6 + B12 Tab Tab (null) 350 

307 D22020 Vitamin C Tab Tab 500mg 350 

308 D21038 Voglibose Tab Tab 0.2mg 350 

309 D21039 Voglibose Tab Tab 0.5mg 350 

310 D15061 Voriconazole Eye Drops Eye Drops 1% 350 

311 

D12013/ 

12 Warfarin Sodium Tab Tab 2mg 350 

312 D12020 Warfarin Sodium Tab Tab 1mg 350 

313 D12021 Warfarin Sodium Tab Tab 5mg 330 

314 D14040 White Soft Paraffin Ip Paraffin 50gm 380 

315 D24053 Zoledronic Acid Inj INJ 4mg/ml 350 

316 D17059 Zolpidem Tab Tab 10mg 350

empanelment of drug testing laboratories - Kerala Medical Services ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?